Lighting Science (LSCG) Inactive 10-Q14 May 142014 Q1 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
Document and Entity Information	Mar. 31, 2014	8-May-14
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Entity Registrant Name	'LIGHTING SCIENCE GROUP CORP	'
Entity Central Index Key	'0000866970	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	209,488,064

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$5,313,075	$11,195,412
Restricted cash	3,000,000	5,000,000
Accounts receivable, net	17,221,908	7,771,623
Inventories, net	21,242,029	19,061,119
Prepaid expenses	2,302,842	1,900,025
Other current assets	239,277	358,740
Total current assets	49,319,131	45,286,919
Property and equipment, net	5,177,047	6,498,605
Intangible assets, net	2,058,954	1,850,411
Pegasus Commitment	1,840,000	1,407,335
Other long-term assets	4,866,230	253,856
Total assets	63,261,362	55,297,126
Current liabilities:	'	'
Lines of credit	10,012,505	40,211,429
Current portion of long-term debt	5,128	4,998
Accounts payable	13,974,689	15,980,466
Provision for losses on non-cancelable purchase commitments	972,893	1,629,806
Accrued expenses	6,981,582	7,180,108
Total current liabilities	31,946,797	65,006,807
Note payable	26,758,539	'
Long-term debt, less current portion	7,014	8,460
Total other liabilities	84,865,476	9,183,506
Total liabilities	116,812,273	74,190,313
Redeemable Convertible Preferred Stock	426,906,776	391,956,776
Commitments and contingencies	'	'
Stockholders' deficit:	'	'
Preferred stock, $.001 par value, authorized 25,000,000 shares, 113,609 shares of Series H, 62,365 shares of Series I and 37,475 shares of Series J issued and outstanding as of March 31, 2014 and 113,609 shares of Series H, 62,365 shares of Series I and 20,000 shares of Series J issued and outstanding as of December 31, 2013	'	'
Common stock, $.001 par value, authorized 475,000,000 shares, 210,355,113 and 210,349,168 shares issued as of March 31, 2014 and December 31, 2013, respectively	210,355	210,349
Additional paid-in capital	301,513,520	331,199,891
Accumulated deficit	-774,827,863	-734,733,900
Accumulated other comprehensive loss	-3,596,199	-3,768,803
Treasury stock, 2,505,000 shares as of March 31, 2014 and December 31, 2013, at cost	-3,757,500	-3,757,500
Total stockholders' deficit	-480,457,687	-410,849,963
Total liabilities and stockholders' deficit	63,261,362	55,297,126
Riverwood Warrants [Member]	'	'
Current liabilities:	'	'
Warrants liability	7,056,079	5,002,664
September 2012 Warrants [Member]	'	'
Current liabilities:	'	'
Warrants liability	1,840,000	1,407,335
Pegasus Warrant [Member]	'	'
Current liabilities:	'	'
Warrants liability	3,900,000	2,765,047
Series J Warrants [Member]	'	'
Current liabilities:	'	'
Warrants liability	38,639,971	'
Medley Warrants [Member]	'	'
Current liabilities:	'	'
Warrants liability	3,245,315	'
Pegasus Guaranty Warrants [Member]	'	'
Current liabilities:	'	'
Warrants liability	3,418,558	'
Series H Redeemable Convertible Preferred Stock [Member]	'	'
Current liabilities:	'	'
Redeemable Convertible Preferred Stock	227,220,149	227,220,149
Series I Redeemable Convertible Preferred Stock [Member]	'	'
Current liabilities:	'	'
Redeemable Convertible Preferred Stock	124,736,627	124,736,627
Series J Redeemable Convertible Preferred Stock [Member]	'	'
Current liabilities:	'	'
Redeemable Convertible Preferred Stock	74,950,000	40,000,000
Stockholders' deficit:	'	'
Additional paid-in capital	$30,200,000	'

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Dec. 31, 2013
	Mar. 31, 2014	Dec. 31, 2013	Series H Redeemable Convertible Preferred Stock [Member]	Series H Redeemable Convertible Preferred Stock [Member]	Series I Redeemable Convertible Preferred Stock [Member]	Series I Redeemable Convertible Preferred Stock [Member]	Series J Redeemable Convertible Preferred Stock [Member]	Series J Redeemable Convertible Preferred Stock [Member]
Preferred stock, par value	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Preferred stock, shares authorized	25,000,000	25,000,000	135,000	135,000	90,000	90,000	50,000	50,000
Preferred stock, shares issued	113,609	113,609	113,609	113,609	62,365	62,365	37,475	20,000
Preferred stock, shares outstanding	113,609	113,609	113,609	113,609	62,365	62,365	37,475	20,000
Common stock, par value	$0.00	$0.00	'	'	'	'	'	'
Preferred stock, shares issued	113,609	113,609	113,609	113,609	62,365	62,365	37,475	20,000
Common stock, shares authorized	475,000,000	475,000,000	'	'	'	'	'	'
Preferred stock, shares outstanding	113,609	113,609	113,609	113,609	62,365	62,365	37,475	20,000
Common stock shares issued	210,355,113	210,349,168	'	'	'	'	'	'
Treasury stock, shares	2,505,000	2,505,000	'	'	'	'	'	'

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Revenue	$25,925,841	$19,981,607
Cost of goods sold (exclusive of depreciation shown below)	23,235,346	18,113,115
Gross profit	2,690,495	1,868,492
Operating expense:	'	'
Selling, distribution and administrative (includes related party expenses of $609,000 and $615,000 for the three months ended March 31, 2014 and 2013, respectively)	9,193,945	13,087,252
Research and development	1,544,024	2,386,843
Restructuring expense	205,052	99,004
Depreciation and amortization	1,076,010	2,265,702
Total operating expenses	12,019,031	17,838,801
Loss from operations	-9,328,536	-15,970,309
Other (expense) income:	'	'
Interest income	411	516
Interest expense	-1,343,225	-875,943
(Increase) decrease in fair value of liabilities under derivative contracts	-29,479,538	361,850
Other income, net	56,925	5,682
Total other expense	-30,765,427	-507,895
Loss before income tax expense	-40,093,963	-16,478,204
Income tax expense	'	'
Net loss	-40,093,963	-16,478,204
Foreign currency translation gain (loss)	172,604	-279,475
Comprehensive loss	($39,921,359)	($16,757,679)
Controlling Shareholders [Member]	'	'
Other (expense) income:	'	'
Basic and diluted net loss per weighted average common share	($0.33)	($0.08)
Basic and diluted weighted average number of common shares outstanding	170,973,536	170,632,589
Noncontrolling Shareholders [Member]	'	'
Other (expense) income:	'	'
Basic and diluted net loss per weighted average common share	($0.35)	($0.08)
Basic and diluted weighted average number of common shares outstanding	36,854,212	34,946,783

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parenthetical) (Selling, Distribution and Administrative Expenses [Member], USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Selling, Distribution and Administrative Expenses [Member]	'	'
Related party expense	$609,000	$615,000

Condensed_Consolidated_Stateme2

Condensed Consolidated Statement of Stockholders' Deficit (Unaudited) (USD $)	Total	Series J Redeemable Convertible Preferred Stock [Member]	Pegasus Warrant [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]	Treasury Stock [Member]
	Total	Series J Redeemable Convertible Preferred Stock [Member]	Pegasus Warrant [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Series J Redeemable Convertible Preferred Stock [Member]	Pegasus Warrant [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]	Treasury Stock [Member]
Balance at Dec. 31, 2013	($410,849,963)	'	'	$210,349	$331,199,891	'	'	($734,733,900)	($3,768,803)	($3,757,500)
Balance, shares at Dec. 31, 2013	'	'	'	210,349,168	'	'	'	'	'	'
Issuance of restricted stock and options for directors' compensation	73,348	'	'	'	73,348	'	'	'	'	'
Issuance of common stock for directors' compensation, shares	'	'	'	'	'	'	'	'	'	'
Stock based compensation expense	916,657	'	'	'	916,657	'	'	'	'	'
Stock issued under equity compensation plans	1,962	'	'	6	1,956	'	'	'	'	'
Stock issued under equity compensation plans, shares	'	'	'	5,945	'	'	'	'	'	'
Warrant issued to a customer	90,861	'	'	'	90,861	'	'	'	'	'
Deemed dividends on Series J Redeemable Convertible Preferred Stock	'	-30,198,619	'	'	'	-30,198,619	'	'	'	'
Deemed dividend for issuance of Pegasus Guaranty Warrants	'	'	-570,574	'	'	'	-570,574	'	'	'
Net loss	-40,093,963	'	'	'	'	'	'	-40,093,963	'	'
Foreign currency translation adjustment	172,604	'	'	'	'	'	'	'	172,604	'
Balance at Mar. 31, 2014	($480,457,687)	'	'	$210,355	$301,513,520	'	'	($774,827,863)	($3,596,199)	($3,757,500)
Balance, shares at Mar. 31, 2014	'	'	'	210,355,113	'	'	'	'	'	'

Condensed_Consolidated_Stateme3

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Cash flows from operating activities:	'	'
Net loss	($40,093,963)	($16,478,204)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	1,076,010	2,265,702
Impairment of plant and equipment	'	1,328
Issuance of restricted stock and stock options for directors' compensation	73,348	20,495
Stock based compensation expense	916,657	2,267,109
Non-cash sales incentive	90,861	31,083
Allowance for doubtful accounts receivable	25,768	'
Inventory write-down	689,637	316,235
Provision for losses on non-cancelable purchase commitments	-112,527	'
Increase (decrease) in fair value of warrants	29,479,538	-361,850
Medley discount accretion	84,399	'
Interest accrued on Medley Term Loan	69,501	'
Loss on disposal of assets	42,690	239,237
Changes in operating assets and liabilities:	'	'
Accounts receivable	-9,459,143	3,994,397
Inventories	-3,396,648	1,352,205
Prepaid expenses	-402,433	-304,119
Other current and long-term assets	-1,726,911	207,240
Accounts payable	-2,005,522	-6,982,666
Accrued expenses and other liabilities	-146,805	-816,080
Net cash used in operating activities	-24,795,543	-14,247,888
Cash flows from investing activities:	'	'
Purchases of property and equipment	-153,420	-510,727
Capitalized patents	-222,175	-372,139
Proceeds from sale of property and equipment	370,100	287,347
Net cash used in investing activities	-5,495	-595,519
Cash flows from financing activities:	'	'
Net (payments) proceeds from draws on lines of credit and other short-term borrowings	-30,198,924	9,023,223
Proceeds from notes payable	29,775,000	'
Payment of short and long-term debt	-1,316	-1,195
Restricted cash related to line of credit	2,000,000	'
Proceeds from issuance of common stock under equity compensation plans	1,962	18,257
Proceeds from issuance of Series J Redeemable Convertible Preferred Stock	17,475,000	'
Placement agent commissions on private placements	-217,880	'
Net cash provided by financing activities	18,833,842	9,040,285
Effect of exchange rate changes on cash	84,859	-415,638
Net decrease in cash	-5,882,337	-6,218,760
Cash and cash equivalents balance at beginning of period	11,195,412	15,834,077
Cash and cash equivalents balance at end of period	5,313,075	9,615,317
Supplemental disclosures:	'	'
Interest paid during the period	1,059,079	815,497
Non-cash investing and financing activities:	'	'
Deemed dividends on Series J Redeemable Convertible Preferred Stock	-30,198,619	'
Deemed dividends on issuance of Pegasus Guaranty Warrants	($570,574)	'

Description_of_Business_and_Ba

Description of Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Description of Business and Basis of Presentation	'
	NOTE 1.	DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION
	Overview
	Lighting Science Group Corporation (the “Company”) was incorporated in Delaware in 1988 and designs, develops, manufactures and markets general illumination products that exclusively use light emitting diodes (“LEDs”) as their light source. The Company’s product portfolio includes LED-based retrofit lamps (replacement bulbs) that can be used in existing light fixtures and sockets as well as purpose built LED-based luminaires (light fixtures) for many common indoor and outdoor residential, commercial, industrial and public infrastructure lighting applications. The Company assembles and manufactures products internally and through its contract manufacturers in Asia.
	Basis of Financial Statement Presentation
	The accompanying unaudited condensed consolidated financial statements are presented pursuant to the rules and regulations of the United States Securities and Exchange Commission (the “SEC”) in accordance with the disclosure requirements for the quarterly report on Form 10-Q and therefore do not include all of the information and footnotes required by generally accepted accounting principles (“GAAP”) for complete financial statements. In the opinion of management, the unaudited condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) necessary to fairly state the results for the interim periods presented. The condensed consolidated balance sheet as of December 31, 2013 is derived from the Company’s audited financial statements. Operating results for the three months ended March 31, 2014 are not necessarily indicative of the results of the Company that may be expected for the year ending December 31, 2014. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements as of and for the year ended December 31, 2013 and notes thereto included in the Company’s Annual Report on Form 10-K originally filed with the SEC on March 31, 2014.
	The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in the accompanying consolidated financial statements.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	NOTE 2.	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. The Company’s actual results could differ from these estimates.
	Restricted Cash
	As of March 31, 2014, as required by the Company’s five-year term loan (the “Medley Term Loan”) with Medley Capital Corporation (“Medley”), the Company was required to maintain a minimum restricted cash balance of $3.0 million to collateralize the Medley Term Loan. As of December 31, 2013, as required by the Company’s asset-based revolving credit facility (as amended, the “Wells Fargo ABL”) with Wells Fargo Bank N.A. (“Wells Fargo”), the Company was required to maintain a minimum qualified cash balance of $5.0 million as a compensating balance against the Wells Fargo ABL. Changes in the restricted cash balance are reflected as a financing activity in the consolidated statement of cash flows.
	Accounts Receivable
	The Company records accounts receivable at the invoiced amount when its products are shipped to customers or upon the completion of specific milestone billing requirements. The Company’s accounts receivable balance is recorded net of allowances for amounts not expected to be collected from customers. This allowance for doubtful accounts is the Company’s best estimate of probable credit losses in the Company’s existing accounts receivable. Estimates used in determining the allowance for doubtful accounts are based on historical collection experience, age of receivables and known collectability issues. The Company writes off accounts receivable when it becomes apparent, based upon age or customer circumstances, that such amounts will not be collected. The Company reviews its allowance for doubtful accounts on a quarterly basis. Recovery of bad debt amounts previously written off is recorded as a reduction of bad debt expense in the period the payment is collected. Generally, the Company does not require collateral for its accounts receivable and does not regularly charge interest on past due amounts. As of March 31, 2014 and December 31, 2013, the Company’s accounts receivable were reflected net of an allowance for doubtful accounts of $436,000 and $475,000, respectively.
	As of March 31, 2014, there were $17.6 million of eligible accounts receivable pledged as collateral for the two year delayed draw term loan (the “Medley Delayed Draw Loan”) entered into on February 19, 2014 with Medley. As of December 31, 2013, there were $6.8 million of eligible accounts receivable pledged as collateral for the Wells Fargo ABL.
	Revenue Recognition
	The Company records revenue when its products are shipped and title passes to customers. When sales of products are subject to certain customer acceptance terms, revenue from such sales is recognized once such terms have been met. The Company also provides its customers with limited rights of return for non-conforming shipments or product warranty claims.
	Product Warranties
	The Company generally provides a five-year limited warranty covering defective materials and workmanship of its products and such warranty may require the Company to repair, replace or reimburse the purchaser for the purchase price of the product. The estimated costs related to warranties are accrued at the time products are sold based on various factors, including the Company’s stated warranty policies and practices, the historical frequency of claims and the cost to repair or replace its products under warranty. The warranty provision is included in accrued expenses on the condensed consolidated balance sheet. Changes in the warranty provision for the three months ended March 31, 2014 were as follows:


	Warranty provision as of December 31, 2013		$	3,231,991
	Additions to provision			509,201
	Less warranty costs			(746,620	)


	Warranty provision as of March 31, 2014		$	2,994,572

	Fair Value Measurements
	Cash and cash equivalents, accounts receivable, accounts payable, amounts due under lines of credit and other short term borrowings, accrued expenses and other current liabilities are carried at amounts that approximate their fair value due to the short-term maturity of these instruments.
	The Riverwood Warrants, September 2012 Warrants and the Pegasus Commitment (each as defined in Note 9 below), the Pegasus Warrants and Series J Warrants, (each as defined in Note 8 below) and Medley Warrants and Pegasus Guaranty Warrants (each as defined in Note 6 below) were initially recorded at fair value and subsequently reflected at their fair value at the end of each reporting period.

Liquidity_and_Capital_Resource

Liquidity and Capital Resources	3 Months Ended
	Mar. 31, 2014
Text Block [Abstract]	'
Liquidity and Capital Resources	'
	NOTE 3.	LIQUIDITY AND CAPITAL RESOURCES
	As shown in the condensed consolidated financial statements, the Company has experienced significant net losses as well as negative cash flows from operations since its inception, resulting in an accumulated deficit of $774.8 million and stockholders’ deficit of $480.5 million as March 31, 2014. The Company’s cash expenditures primarily relate to procurement of inventory, payment of salaries, employee benefits and other operating costs. The Company’s primary sources of liquidity have historically been borrowings from Wells Fargo under a credit facility, which facility was replaced by a borrowing facility with Medley in February 2014, and sales of the Company’s common stock, par value $0.001 per share (the “Common Stock”) and the Company’s preferred stock, par value $0.001 per share (the “Preferred Stock”) to, and short-term loans from, affiliates of Pegasus Capital Advisors, L.P. (“Pegasus Capital”), including Pegasus Partners IV, L.P. (“Pegasus IV”), LSGC Holdings, LLC (“LSGC Holdings”), LSGC Holdings II, LLC (“Holdings II”) and PCA LSG Holdings, LLC (“PCA Holdings”), which together with its affiliates, is the Company’s controlling stockholder. While affiliates of Pegasus Capital have led many of our capital raises, the Series J Preferred Offering and the Series H and I Preferred Offering, (defined in Note 9 below) also involved parties other than Pegasus Capital and its affiliates.
	On February 19, 2014, the Company entered into an agreement with Medley (the “Medley Loan Agreement”) pursuant to which the Company obtained a five-year term loan in the amount of $30.5 million and the Medley Delayed Draw Loan. The Company utilized proceeds from the Medley Term Loan to repay its outstanding obligations under the Wells Fargo ABL and the Ares Letter of Credit Facility.

	As of March 31, 2014, the Company had cash and cash equivalents of $5.3 million and an additional $3.0 million in restricted cash subject to a cash collateral dominion agreement pursuant to the Medley Term Loan. The Medley Delayed Draw Loan provides the Company with a borrowing capacity of up to $22.5 million, which capacity is equal to the sum of (i) 85% of the Company’s eligible accounts receivable, (ii) 60% of the Company’s eligible inventory, and (iii) qualified cash less any reserves imposed by Medley for the benefit of the Company (collectively, the “Borrowing Base”). The Company is at all times required to maintain (i) a Borrowing Base that exceeds the amount of its outstanding borrowings under the Medley Delayed Draw Loan and (ii) $3.0 million in restricted cash. The Company is required to comply with certain specified EBITDA requirements, maintain a specified lamp sourcing percentage and comply with a maximum capital expenditure limits.
	The Company believes that it will have sufficient capital to fund its operations for at least the next 12 months based on its current business plan and assumptions of future results. The Company’s current business plan includes a focus on increasing revenue by updating and expanding its product offerings and capitalizing on the known product needs of its existing customers, improving gross margins by significantly leveraging contract manufacturers in Asia and reducing operating costs, primarily through the restructuring initiated in 2013. In future periods, if the Company does not adequately execute upon its business plan or its assumptions or forecasts do not prove to be accurate, the Company could exhaust its available capital resources, which could require the Company to seek to raise additional capital and/or further reduce its expenditures of cash. However, sources of liquidity may not be available in an amount or on terms that are acceptable to the Company.

Detail_of_Certain_Balance_Shee

Detail of Certain Balance Sheet Accounts	3 Months Ended
Detail of Certain Balance Sheet Accounts	Mar. 31, 2014
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'
Detail of Certain Balance Sheet Accounts	'
	NOTE 4.	DETAIL OF CERTAIN BALANCE SHEET ACCOUNTS
	Inventories
	Inventories consisted of the following as of the dates indicated:


			March 31, 2014			December 31, 2013

	Raw materials and components		$	4,284,989		$	6,868,139
	Work-in-process			524,641			1,599,089
	Finished goods			16,432,399			10,593,891


	Total inventory, net		$	21,242,029		$	19,061,119

	Consigned inventory is held at third-party locations, including those of the Company’s contract manufacturers. The Company retains title to the consigned inventory until such inventory is purchased by a third-party. Consigned inventory, consisting of raw materials, was $963,000 and $693,000 as of March 31, 2014 and December 31, 2013, respectively.
	As of March 31, 2014 and December 31, 2013, inventories were stated net of inventory write downs of $23.9 million and $24.1 million, respectively. The Company considered a number of factors in estimating the required inventory write downs, including (i) the focus of the business on the next generation of the Company’s products, which utilize lower cost technologies, (ii) the strategic focus on core products to meet the demands of key customers and (iii) the expected demand for the Company’s current generation of products, which are approaching the end of their lifecycle upon the introduction of the next generation of products.

	Property and Equipment, Net
	Property and equipment, net consisted of the following as of the dates indicated:


			March 31, 2014			December 31, 2013

	Leasehold improvements		$	1,495,681		$	1,486,628
	Office furniture and equipment			1,140,269			1,141,314
	Computer hardware and software			9,035,364			8,802,484
	Tooling, production and test equipment			15,078,146			16,141,358
	Vehicles			1,420			—
	Construction-in-process			152,606			325,252

	Total property and equipment			26,903,486			27,897,036
	Accumulated depreciation			(21,726,439	)		(21,398,431	)


	Total property and equipment, net		$	5,177,047		$	6,498,605

	Depreciation related to property and equipment was $1.1 million and $2.3 million for the three months ended March 31, 2014 and 2013, respectively.

Intangible_Assets

Intangible Assets

3 Months Ended

Mar. 31, 2014

Goodwill And Intangible Assets Disclosure [Abstract]

Intangible Assets

NOTE 5.

INTANGIBLE ASSETS

Intangible assets that have finite lives are amortized over their useful lives. The Company’s intangible assets are detailed below as of March 31, 2014 and December 31, 2013:

Cost, Less

Accumulated

Net Book

Estimated

Impairment

Amortization

Value

Remaining

Charges

Useful Life

March 31, 2014:

Technology and intellectual property

2,233,829

(174,875

)

2,058,954

2.4 to 20.0 years

December 31, 2013:

Technology and intellectual property

2,011,654

(161,243

)

1,850,411

2.7 to 20.0 years

Total intangible amortization expense was $14,000 and $6,000 for the three months ended March 31, 2014 and 2013, respectively.

Lines_of_Credit_And_Note_Payab

Lines of Credit And Note Payable	3 Months Ended
	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Lines of Credit And Note Payable	'
	NOTE 6.	LINES OF CREDIT AND NOTE PAYABLE

	Medley Delayed Draw Loan

	On February 19, 2014, the Company, entered into the Medley Delayed Draw Loan. The Medley Delayed Draw Loan may be borrowed and re-borrowed on a revolving basis by the Company, from the closing date through June 2014 (the “Revolving Loan Termination Date”). Following the Revolving Loan Termination Date, the remaining maximum amount of the Medley Delayed Draw Loan may be drawn by the Company from time to time, provided that such loan may not be re-borrowed once repaid, subject to certain exceptions. Borrowings under the Medley Delayed Draw Loan are limited by a borrowing base equal to the sum of (i) 85% of eligible accounts, (ii) 60% of inventory, and (iii) qualified cash, less any reserves imposed by Medley. Each draw on the Medley Delayed Draw Loan made by the Company after June 30, 2014 is subject to a $2.0 million liquidity requirement and the payment of a funding fee based upon the amount of the applicable draw being funded. As of March 31, 2014, the Company had $10.0 million outstanding under the Medley Delayed Draw Loan and additional borrowing capacity of $12.5 million.

	As of March 31, 2014, eligible collateral included $17.6 million of accounts receivable, $19.8 million of inventory and $5.3 million of qualified cash. From February 19, 2014 through the Revolving Loan Termination Date, the Medley Delayed Draw Loan bears interest at a floating rate equal to three month LIBOR plus 10.5% per annum, payable in cash monthly in arrears. As of March 31, 2014, the interest rate on the Medley Delayed Draw Loan was 10.7%. Following the Revolving Loan Termination Date, the Medley Delayed Draw Loan bears interest equal to three month LIBOR plus 12% per annum, as follows: (i) up to 2% (at the Company’s election) of interest may be paid as “payment in kind” by adding such accrued interest to the unpaid principal balance of the Medley Term Loan and (ii) the remainder is payable in cash monthly in arrears. The outstanding principal balance and all accrued and unpaid interest on the Medley Delayed Draw Loan is due and payable on February 19, 2016.



	Medley Term Loan

	On February 19, 2014, the Company, entered into the Medley Term Loan in the amount of $30.5 million. The Medley Term Loan bears interest at a floating rate equal to three-month LIBOR plus 12% per annum, as follows: (i) up to 2% (at the Company’s election) of interest may be paid as “payment in kind” by adding such accrued interest to the unpaid principal balance of the term loan and (ii) the remaining accrued interest amount is payable in cash monthly in arrears. As of March 31, 2014, the interest rate on the Medley Term Loan was 12.2%. Additionally, $3.0 million of the Medley Term Loan was funded directly into a deposit account in which Medley has exclusive access, to further secure the loan. The outstanding principal balance and all accrued and unpaid interest on the Medley Term Loan are due and payable on February 19, 2019. As of March 31, 2014 the balance of the Medley Term Loan was $26.8 million, which included the initial loan balance of $30.5 million offset by a discount of $725,000 related to the commitment fees paid to Medley and a discount of $3.2 million related to the Medley Warrants (discussed below). In addition, the Company recognized and $84,000 accretion of the discounts to the balance of the Medley Term Loan related to the commitment fees and the Medley Warrants and $70,000 of accrued interest for the period from February 19, 2014 to March 31, 2014.

	Medley Warrants

	On February 19, 2014, and in connection with the consummation of the transactions contemplated by the Medley Loan Agreement, the Company issued a warrant to purchase 5,000,000 shares of Common Stock to each of Medley and Medley Opportunity Fund II LP (the “Medley Warrants”). The Medley Warrants have an exercise price equal to $0.95 and, if unexercised, expire on February 19, 2024. The Medley Warrants were not exercisable until the Company amended its Certificate of Incorporation to increase the number of authorized shares of Common Stock to a number sufficient to permit the Company to reserve shares of Common Stock for issuance upon the exercise or conversion in full of all of the Company’s outstanding securities that are convertible into or exercisable or exchangeable for shares of Common Stock (the “Charter Amendment”). The Charter Amendment was effective April 14, 2014.

	The Medley Warrants are considered derivative financial instruments in accordance with ASC 815-10-15, “Derivatives and Hedging” due to the down round protection provided to the holders by the instruments. The Medley Warrants were recorded as a liability at fair value using the Black Scholes valuation method at issuance and were valued at $3.2 million as of February 19, 2014, which was recorded as a discount to the Medley Term Loan. The discount is being accreted using the effective interest rate method over the life of the loan as a non-cash charge to interest expense. Changes in fair value of the Medley Warrants are measured and recorded at the end of each quarter. The change in fair value of the Medley Warrants was $75,000 for the period from February 19, 2014 (the date of issuance of the Medley Warrants) to March 31, 2014, and was included in the (increase) decrease in fair value of liabilities under derivative contracts in the consolidated statement of operations and comprehensive loss. Accretion of the discount on the Medley Term Loan for the period from February 19, 2014 to March 31, 2014 of $69,000 was included in interest expense.

	On February 19, 2014, the Company also entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with Medley and Medley Opportunity Fund II LP pursuant to which the Company granted piggyback registration rights with respect to the shares of Common Stock underlying the Medley Warrants and any other shares of Common Stock that may be acquired by such parties in the future.

	Pegasus Guaranty and Pegasus Guaranty Warrants

	Pegasus Capital Partners IV, L.P. and Pegasus Capital Partners V, L.P. (collectively, the “Pegasus Guarantors”) have agreed to provide a guaranty of the Company’s obligations under the Medley Loan Agreement in favor of Medley (the “Pegasus Guaranty”). The Pegasus Guaranty was recorded as debt issuance costs at fair value on the date of issuance. The fair value was determined to be $2.8 million as of February 19, 2014, using an implied interest rate analysis. The debt issuance costs will be amortized as non-cash interest expense over the life of the Medley Term Loan. As consideration for the Pegasus Guaranty, on February 19, 2014, the Company issued a warrant to purchase 5,000,000 shares of Common Stock to each of the Pegasus Guarantors (the “Pegasus Guaranty Warrants”). The Pegasus Guaranty Warrants have an exercise price equal to $0.50 and, if unexercised, expire on February 19, 2024. The Pegasus Guaranty Warrants were not exercisable until the Company effected the Charter Amendment. The Charter Amendment was effective April 14, 2014.

	The Pegasus Guaranty Warrants are considered derivative financial instruments in accordance with ASC 815-10-15, “Derivatives and Hedging” due to the down round protection provided by the instrument. The Pegasus Guaranty Warrants were recorded as a liability at fair value using the Black Scholes valuation method at issuance and were valued at $3.3 million as of February 19, 2014. The fair value of the Pegasus Guaranty partially offset the fair value of the Pegasus Guaranty Warrants, with the remaining value of $571,000 accounted for as a deemed dividend to the Company’s controlling stockholder. Changes in fair value of the Pegasus Guaranty Warrants are measured and recorded at the end of each quarter. The change in fair value of the Pegasus Guaranty Warrants was $82,000 for the period from February 19, 2014 (the date of issuance of the Pegasus Guaranty Warrants) to March 31, 2014, and was included in the (increase) decrease in fair value of liabilities under derivative contracts in the consolidated statement of operations and comprehensive loss.

	Wells Fargo

	The Wells Fargo ABL provided the Company with borrowing capacity of up to $50.0 million, which capacity was equal to the sum of (i) 85% of its eligible accounts receivable plus $7.5 million of eligible inventory less certain allowances established against such accounts receivable and inventory by Wells Fargo from time to time pursuant to the Wells Fargo ABL, plus (ii) qualified cash, plus (iii) the amount of the Ares Letter of Credit Facility. On February 19, 2014, the Company utilized proceeds from the Medley Term Loan to repay its outstanding obligations under the Wells Fargo ABL.

	Borrowings under the Wells Fargo ABL bore interest at one of the following two rates (at the Company’s election): (a) the sum of (1) the greater of: (x) the federal funds rate plus 0.50%, (y) the daily three month LIBOR rate plus 1.0% and (z) Wells Fargo’s prime rate; and (2) 0.75%, 1.25% or 1.75%, as applicable, depending on the amount available for borrowing under the facility and subject to any reserves established by Wells Fargo in accordance with the terms of the Wells Fargo ABL; or (b) the sum of the daily three month LIBOR rate plus 3.0%, 3.5% or 4.0%, as applicable, depending on the amount available for borrowing under the facility and subject to any reserves established by Wells Fargo in accordance with the terms of the facility.

	Ares Capital

	On September 21, 2011, the Company entered into the Ares Letter of Credit Facility, a $25.0 million standby letter of credit issued by Ares Capital in favor of Wells Fargo for the benefit of the Company. On February 19, 2014, the Company utilized proceeds from the Medley Term Loan to repay its outstanding obligations under the Ares Letter of Credit Facility.

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
Fair Value Measurements	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	NOTE 7.	FAIR VALUE MEASUREMENTS
	The Fair Value Measurements and Disclosures Topic of the Financial Accounting Standards Board Accounting Standards Codification (“ASC”) defines fair value as the price at which an asset could be exchanged in a current transaction between knowledgeable, willing parties. A liability’s fair value is defined as the amount that would be paid to transfer the liability to a new obligor, not the amount that would be paid to settle the liability with the creditor.
	Assets and liabilities measured at fair value are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels are directly related to the amount of subjectivity associated with the inputs to a fair valuation of these assets and liabilities and are based on (i) unadjusted quoted prices that are available in active markets for the identical assets or liabilities at the measurement date (Level 1); (ii) quoted prices in non-active markets or inputs that are observable either directly or indirectly for substantially the full term of the asset or liability (Level 2); and (iii) prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement (Level 3).
	The Company has recorded the Series J Warrants, the Medley Warrants and the Pegasus Guaranty Warrants at their fair values using the Black Scholes valuation method and they are valued on a recurring basis at the end of each reporting period. The Company has recorded the Pegasus Warrants (as defined in Note 8 below), the Riverwood Warrants, the September 2012 Warrants and the Pegasus Commitment (each as defined in Note 9 below) at their fair values using the Monte Carlo valuation method and they are valued on a recurring basis at the end of each reporting period.

	The following table sets forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of March 31, 2014, according to the valuation techniques the Company used to determine their fair values:


			Fair Value Measurement as of March 31, 2014
			Quoted Price in			Significant Other			Significant
			Active Markets for			Observable Inputs			Unobservable Inputs
			Identical Assets
			Level 1			Level 2			Level 3

	Assets (Recurring):
	Pegasus Commitment		$	—		$	—		$	1,840,000


	Liabilities (Recurring):
	Riverwood Warrants		$	—		$	—		$	7,056,079
	September 2012 Warrants			—			—			1,840,000
	Pegasus Warrant			—			—			3,900,000
	Series J Warrants			—			—			38,639,971
	Medley Warrants			—			—			3,245,315
	Pegasus Guaranty Warrants			—			—			3,418,558

			$	—		$	—		$	58,099,923

	The following table is a reconciliation of the beginning and ending balances for assets and liabilities that were accounted for at fair value on a recurring basis using Level 3 inputs, as defined above, for the three months ended March 31, 2014:


			Balance			Realized and unrealized			Purchases, sales,			Transfers in		Balance
			December 31, 2013			gains (losses) included			issuances and			or out of		March 31, 2014
						in net loss			settlements			Level 3
	Pegasus Commitment		$	1,407,335		$	432,665		$	—		$	—	$	1,840,000
	Riverwood Warrants			(5,002,664	)		(2,053,415	)		—			—		(7,056,079	)
	September 2012 Warrants			(1,407,335	)		(432,665	)		—			—		(1,840,000	)
	Pegasus Warrant			(2,765,047	)		(1,134,953	)		—			—		(3,900,000	)
	Series J Warrants			—			(26,134,232	)		(12,505,739	)				(38,639,971	)
	Medley Warrants			—			(74,954	)		(3,170,361	)		—		(3,245,315	)
	Pegasus Guaranty Warrants			—			(81,984	)		(3,336,574	)		—		(3,418,558	)


	Total		$	(7,767,711	)	$	(29,479,538	)	$	(18,012,674	)	$	—	$	(56,259,923	)

	The following table is a reconciliation of the beginning and ending balances for assets and liabilities that were accounted for at fair value on a recurring basis using Level 3 inputs, as defined above, for the three months ended March 31, 2013:


			Balance			Realized and unrealized			Purchases, sales,			Transfers in		Balance
			December 31, 2012			gains (losses) included			issuances and			or out of		March 31, 2013
						in net loss			settlements			Level 3
	Pegasus Commitment		$	1,360,000		$	160,000		$	—		$	—	$	1,520,000
	Riverwood Warrants			(7,960,705	)		361,850			—			—		(7,598,855	)
	September 2012 Warrants			(1,360,000	)		(160,000	)		—			—		(1,520,000	)


	Total		$	(7,960,705	)	$	361,850		$	—		$	—	$	(7,598,855	)

Series_J_Redeemable_Convertibl

Series J Redeemable Convertible Preferred Stock	3 Months Ended
	Mar. 31, 2014
Text Block [Abstract]	'
Series J Redeemable Convertible Preferred Stock	'
	NOTE 8.	SERIES J REDEEMABLE CONVERTIBLE PREFERRED STOCK
	Initial Series J Offering
	From September 11, 2013 through November 18, 2013, the Company issued an aggregate of 20,000 shares of its Series J Preferred Stock, par value $0.001 per share (the “Series J Preferred Stock”), at a price of $1,000 per share (the “Stated Value”) for aggregate proceeds of $20.0 million (the “Initial Series J Preferred Offering”). The shares of Series J Preferred Stock were issued pursuant to a preferred stock subscription agreement (the “Series J Subscription Agreement”) entered into between the Company, PCA Holdings, Holdings II and RW LSG Holdings LLC, (“Riverwood Holdings”), an affiliate of Riverwood LSG Management Holdings LLC (“Riverwood Management”) and Riverwood Capital Partners L.P. (“Riverwood Capital,” and together with Riverwood Holdings, Riverwood Management and their affiliates, “Riverwood”). The Company issued 13,657, 2,500, 2,394 and 1,449 shares of Series J Preferred Stock to Holdings II, PCA Holdings, Riverwood Holdings and other accredited investors, respectively. As compensation for advisory services provided by Pegasus, on September 11, 2013 the Company issued a warrant to Holdings II, (the “Pegasus Warrant”) representing the right to purchase 10,000,000 shares of Common Stock at a variable exercise price that will be determined on the date of exercise.

	The Series J Preferred Stock is senior to the Series H Preferred Stock, the Series I Preferred Stock and the Common Stock and is entitled to dividends of the same type as any dividends or other distribution of any kind payable or to be made on outstanding shares of Common Stock, on an as converted basis. Each share of Series J Preferred Stock is convertible at any time, at the election of the holder thereof, into the number of shares of Common Stock (the “Optional Conversion Shares”) equal to the quotient obtained by dividing (a) the Stated Value of such shares of Series J Preferred Stock by (b) the $0.95 conversion price, subject to certain adjustments.
	The Company is required to redeem all outstanding shares of Series J Preferred Stock for an amount in cash equal to the Liquidation Amount (as defined below) upon the Company’s receipt of a notice from the holders of Series H Preferred Stock that would require the Company to redeem the shares of Series H Preferred Stock pursuant to the Series H Certificate of Designation. The redemption of any shares of Series J Preferred Stock would be senior and prior to any redemption of Series H Preferred Stock or Series I Preferred Stock and any holder of shares of Series J Preferred Stock may elect to have less than all or none of such holder’s shares of Series J Preferred Stock redeemed. At any time after the Company has redeemed any shares of Series H Preferred Stock, at any time thereafter each holder of shares of Series J Preferred Stock may elect to have all or a portion of such holder’s shares of Series J Preferred Stock redeemed by the Company for an amount in cash equal to the Liquidation Amount of such shares of Series J Preferred Stock.
	The “Liquidation Amount” of each share of Series J Preferred Stock is equal to the greater of (a) the fair market value of the Optional Conversion Shares and (b) if the applicable reference date occurs (i) on or prior to May 26, 2014, an amount equal to the product obtained by multiplying (A) the Stated Value by (B) 1.75; and (ii) subsequent to May 26, 2014, an amount equal to the product obtained by multiplying (A) the Stated Value by (B) 2.0.
	Follow-On Series J Offering
	Between January 3, 2014 and March 7, 2014, the Company issued an aggregate of 17,475 units of its securities (the “Series J Securities”), at a purchase price of $1,000 per Series J Security for aggregate proceeds of $17.5 million (the “Follow-On Series J Offering”). Each Series J Security consists of (i) one share of the Company’s Series J Preferred Stock and (ii) a warrant to purchase 2,650 shares of Common Stock, at an exercise price of $0.001 per share (the “Series J Warrants”). The Series J Securities were issued pursuant to separate Series J Securities Subscription Agreements (the “Follow-On Subscription Agreements”) between the Company, PCA Holdings, Holdings II, Riverwood Holdings, Cleantech Europe II (A) LP (“Cleantech A”) and Cleantech Europe II (B) LP (“Cleantech B” and together with Cleantech A, “Zouk”) and certain other accredited investors. The Company issued 6,000, 6,000, 2,860, 2,570 and 45 shares of Series J Preferred Stock to Holdings II, PCA Holdings, Riverwood Holdings, Zouk and other accredited investors, respectively.
	The Follow-On Series J Offering was deemed to be a “Qualified Follow-On”, as such term is used and defined in the Series J Certificate of Designation and the Preferred Stock Subscription Agreements (the “Existing Subscription Agreements”) by and between the Company and the existing holders of Series J Preferred Stock (the “Initial Series J Investors”). As a result, and in accordance with the Existing Subscription Agreements, the Initial Series J Investors exchanged their Series J Preferred Stock for Series J Securities (the “Series J Exchange”).
	Accordingly, on January 3, 2014, each of LSGC Holdings II, PCA LSG and Riverwood Holdings received Series J Warrants to purchase 36,191,050, 6,625,000 and 6,344,100 shares of Common Stock, respectively, in addition to the shares of Series J Preferred Stock purchased pursuant to the Existing Subscription Agreements. Pursuant to the terms of the Series J Certificate of Designation and the Existing Subscription Agreement, because Holdings II, PCA Holdings and Riverwood Holdings collectively held at least a majority of the issued and outstanding shares of Series J Preferred Stock and elected to participate in the Series J Exchange with respect to all of their previously purchased shares of Series J Preferred Stock, all of the Initial Series J Investors were required to participate in the Series J Exchange. As of March 7, 2014, the Company had issued an aggregate of 37,475 shares of Series J Preferred Stock and Series J Warrants to purchase 99,308,750 shares of Common Stock.
	In the Initial Series J Preferred Offering and the Follow-On Series J Offering, the Company issued an aggregate of 19,657 Series J Securities to Holdings II, 8,500 Series J Securities to PCA Holdings, 5,254 Series J Securities to Riverwood, 2,570 Series J Securities to Zouk and 1,494 Series J Securities to certain other accredited investors.
	In accordance with ASC 480, “Distinguishing Liabilities from Equity,” the shares of Series J Preferred Stock are recorded as mezzanine equity because such shares contain terms that allow the holder to redeem the shares for cash, and for which redemption is not solely within the control of the Company. In accordance with ASC 480-10-S99, the Company will recognize changes in the redemption value immediately as they occur and adjust the carrying amount of the shares of Series J Preferred Stock to equal the redemption value at the end of each reporting period. The Series J Preferred Stock was recorded at redemption value on each date of issuance, which included a deemed dividend due to the redemption feature. As of March 31, 2014, Series J Preferred Stock redemption value included an aggregate deemed dividend of $30.2 million with an offset in additional paid-in capital.

	Pegasus Warrant
	The Pegasus Warrant was issued to Holdings II on September 11, 2013, in consideration for advisory services provided by Pegasus. The Pegasus Warrant represents the right to purchase 10,000,000 shares of Common Stock at a variable exercise price that will be determined on the date of exercise. The exercise price will be equal to the difference obtained by subtracting (a) the fair market value for each share of Common Stock on the day immediately preceding the date of exercise from (b) the quotient obtained by dividing (i) approximately 2.764% of the amount by which the total equity value of the Company exceeds $523.9 million (as may be adjusted for subsequent capital raises) by (ii) the number of shares of Common Stock underlying the Pegasus Warrant; provided that for so long as the total equity value of the Company is less than or equal to $523.9 million (as may be adjusted for subsequent capital raises) the Pegasus Warrant will not be exercisable. The Pegasus Warrant provides for certain anti-dilution adjustments and if unexercised, expires on May 25, 2022.
	The Pegasus Warrant is considered a derivative financial instrument in accordance with ASC 815-10-15, “Derivatives and Hedging” due to the variable nature of the warrant exercise price. The Pegasus Warrant was recorded as a liability at fair value using the Monte Carlo valuation method at issuance with changes in fair value measured and recorded at the end of each quarter. There was an increase in fair value of the Pegasus Warrant of $1.1 million for the three months ended March 31, 2014, which was included in the (increase) decrease in fair value of liabilities under derivative contracts in the consolidated statement of operations and comprehensive loss.
	Series J Warrants
	Each Series J Warrant represents the right to purchase one share of Common Stock at an exercise price $0.001 and if unexercised, expires on January 3, 2019. The Series J Warrants are considered derivative financial instruments in accordance with ASC 815, “Derivatives and Hedging” due to the Company not having adequate shares available for issuance on the date that such warrants were issued. The Series J Warrants were recorded as a liability of $12.4 million based on an allocated portion of the cash proceeds of the Follow on Series J Offering at issuance. Changes in fair value are measured and recorded at the end of each quarter using the Black Scholes valuation method. The change in fair value of the Series J Warrants was $26.1 million for the period from date of issuance of the Series J Warrants to March 31, 2014, and was included in the (increase) decrease in fair value of liabilities under derivative contracts in the consolidated statement of operations and comprehensive loss. The Series J Warrants were not exercisable until the Company effected the Charter Amendment. The Charter Amendment was effective April 14, 2014, at which point the Series J Warrants were deemed equity instruments.

Series_H_and_Series_I_Redeemab

Series H and Series I Redeemable Convertible Preferred Stock	3 Months Ended
	Mar. 31, 2014
Text Block [Abstract]	'
Series H and Series I Redeemable Convertible Preferred Stock	'
	NOTE 9.	SERIES H AND SERIES I REDEEMABLE CONVERTIBLE PREFERRED STOCK
	Series H and I Preferred Stock
	On May 25, 2012, the Company entered into a preferred stock subscription agreement (the “Series H and I Subscription Agreement”) with Riverwood and certain other purchasers, pursuant to which the Company issued 60,705 shares of Series H Convertible Preferred Stock (the “Series H Preferred Stock”) and 6,364 shares of Series I Convertible Preferred Stock (the “Series I Preferred Stock” and together with the Series H Preferred Stock, the “Series H and I Preferred Shares”) at a price of $1,000 per Preferred Share (the “Series H and I Preferred Offering”), for gross proceeds of $67.1 million. In conjunction with the Series H and I Preferred Offering, the Company entered into a Support Services Agreement (the “Riverwood Support Services Agreement”) with Riverwood Holdings and Riverwood Management. As compensation for Riverwood’s provision of certain financial and structural analysis, due diligence investigations, corporate strategy and other advice and negotiation assistance to the Company in connection with the Series H and I Preferred Offering, the Company issued a warrant to Riverwood Management (the “Riverwood Warrant”) representing the right to purchase 18,092,511 shares of Common Stock at a variable exercise price.
	On September 25, 2012, the Company also entered into a separate preferred stock subscription agreement (together, the “September 2012 Subscription Agreements”) with each of (i) Portman Limited (“Portman”) and (ii) Zouk, pursuant to which the Company issued 49,000 shares of Series H Preferred Stock at a price of $1,000 per shares of Series H Preferred Stock (the “September 2012 Preferred Offering”), for gross proceeds of $49.0 million. In conjunction with the September 2012 Preferred Offering, the Company also issued warrants to each of Portman, Cleantech A and Cleantech B to purchase 4,000,000, 3,406,041 and 593,959 shares of Common Stock, respectively (the “September 2012 Warrants”).
	The Series H and I Preferred Shares are entitled to dividends of the same type as any dividends or other distribution of any kind payable or to be made on outstanding shares of Common Stock, on an as converted basis. Each Preferred Share is convertible at any time, at the election of the holder thereof, into the number of shares of Common Stock (the “Optional Conversion Shares”) equal to the quotient obtained by dividing (a) the Stated Value of such Preferred Share by (b) the $0.95 conversion price, subject to certain adjustments.
	In accordance with ASC 480, “Distinguishing Liabilities from Equity,” the Series H and I Preferred Shares are recorded as mezzanine equity because the Series H and I Preferred Shares contain terms that allow the holder to redeem the shares for cash, and for which redemption is not solely within the control of the Company. In accordance with ASC 480-10-S99, the Company will recognize changes in the redemption value immediately as they occur and adjust the carrying amount of the Series H and I Preferred Shares to equal the redemption value at the end of each reporting period. There was no change in the redemption value as of March 31, 2014.
	In connection with the issuance of the September 2012 Warrants, on September 25, 2012, the Company entered into a Commitment Agreement (the “September 2012 Commitment Agreement”) with Pegasus, pursuant to which the Company is obligated to buy from Pegasus IV or its affiliates shares of Common Stock equal to the number of shares, if any, for which the September 2012 Warrants are exercised, up to an aggregate number of shares of Common Stock equal to the aggregate number of shares of Common Stock underlying all of the September 2012 Warrants (the “Pegasus Commitment”). The purchase price for any shares of Common Stock purchased by the Company pursuant to the Pegasus Commitment will be equal to the consideration paid to the Company pursuant to the September 2012 Warrants. With respect to any September 2012 Warrants exercised on a cashless basis, the consideration to Pegasus IV in exchange for the number of shares of Common Stock issued to the exercising holder of September 2012 Warrants would be the reduction in the Pegasus Commitment equal to the reduction in the number of shares underlying the September 2012 Warrants.
	Subject to certain limitations, Pegasus IV has the right to cancel its obligations to the Company pursuant to the September 2012 Commitment Agreement with respect to all or a portion of the Pegasus Commitment then outstanding (a “Pegasus Call”). Upon the exercise of a Pegasus Call, the Company will have the obligation to purchase that number of September 2012 Warrants equal to the Pegasus Commitment subject to the Pegasus Call for an amount equal to the consideration paid by Pegasus IV pursuant to such Pegasus Call.
	Riverwood Warrants
	The Riverwood Warrants were issued to Riverwood Management on May 25, 2012 in consideration for services provided in connection with the Series H and I Preferred Offering. The Riverwood Warrants represent the right to purchase 18,092,511 shares of Common Stock at an exercise price to be determined on the date of exercise. The exercise price will be equal to the difference obtained by subtracting (a) the fair market value for each share of Common Stock on the day immediately preceding the date of exercise from (b) the quotient obtained by dividing (i) 5% of the amount by which the total equity value of the Company exceeds $523.9 million (as may be adjusted for subsequent capital raises) by (ii) the number of shares of Common Stock underlying the Riverwood Warrants; provided that for so long as the total equity value of the Company is less than or equal to $523.9 million (as may be adjusted for subsequent capital raises) the Riverwood Warrants will not be exercisable. The Riverwood Warrants provide for certain anti-dilution adjustments and if unexercised, expires on May 25, 2022.
	The Riverwood Warrants are considered derivative financial instruments in accordance with ASC 815-10-15, “Derivatives and Hedging” due to the variable nature of the exercise price. The Riverwood Warrants were recorded as a liability at fair value using the Monte Carlo valuation method at issuance with changes in fair value measured and recorded at the end of each quarter. The change in fair value of the Riverwood Warrants was an increase of $2.1 million and a decrease of $362,000 for the three months ended March 31, 2014 and 2013, respectively, and was included in the (increase) decrease in fair value of liabilities under derivative contracts in the consolidated statement of operations and comprehensive loss.
	September 2012 Warrants and September 2012 Commitment Agreement
	The September 2012 Warrants are exercisable on or after the tenth business day following the third anniversary of the Issuance Date at an exercise price of $0.72 per share of Common Stock. If unexercised, the September 2012 Warrants expire upon the earlier of (i) a Change of Control of the Company (as defined in the Series H Certificate of Designation) prior to the three-year anniversary of the Issuance Date; (ii) the occurrence of any event that results in holders of shares of Series H Preferred Stock having a right to require the Company to redeem the shares of Series H Preferred Stock prior to the three-year anniversary of the Issuance Date; (iii) consummation of a qualified public offering (“QPO”) (as defined in the Series H Certificate of Designation) prior to the three-year anniversary of the Issuance Date or (iv) receipt by the Company of a Redemption Notice (as defined in the Subscription Agreements). The September 2012 Warrants also provide for certain anti-dilution adjustments.

	The September 2012 Warrants are considered derivative financial instruments in accordance with ASC 815-10-15, “Derivatives and Hedging” due to the cash settlement feature in the instrument. The September 2012 Warrants were recorded as a liability at fair value using the Monte Carlo valuation method at issuance with changes in fair value measured and recorded at the end of each quarter. The change in fair value of the September 2012 Warrants was an increase of $433,000 and an increase of $160,000 for the three months ended March 31, 2014 and 2013, respectively, and was included in additional paid-in capital.
	The Pegasus Commitment is classified as a financial instrument under ASC 480, “Distinguishing Liabilities from Equity” due to the Company’s obligation to purchase its own shares in the event the September 2012 Warrants are exercised by the holders. The Pegasus Commitment was recorded as an asset at fair value using the Monte Carlo valuation method at issuance with changes in fair value measured and recorded at the end of each quarter. The change in fair value of the Pegasus Commitment was $433,000 and $160,000 for the three months ended March 31, 2014 and 2013, respectively, and was included in additional paid-in capital. The change in fair value of the Pegasus Commitment generally offsets the change in fair value of the September 2012 Warrants for the same period.

Stockholders_Equity

Stockholders' Equity	3 Months Ended
Stockholders' Equity	Mar. 31, 2014
Equity [Abstract]	'
Stockholders' Equity	'
	NOTE 10.	STOCKHOLDERS’ EQUITY
	For the three months ended March 31, 2014 and 2013, the Company recorded expenses of $73,000 and $0, respectively, related to restricted stock awards to the Company’s directors and $0 and $20,000, respectively, related to stock options issued to the Company’s directors.
	On January 2, 2013, Jeremy S. M. Cage was appointed Chief Executive Officer and the Company issued 1,000,000 shares of restricted stock to Mr. Cage as part of his compensation package. On March 22, 2013, the Company issued 192,308 shares of restricted stock to Brad Knight as part of his compensation package. For the three months ended March 31, 2013, the Company recorded a $21,000 expense related to the restricted stock award issued to Messrs. Cage and Knight.
	Warrants for the Purchase of Common Stock
	On January 13, 2011, the Company issued a warrant (the “THD Warrant”) to The Home Depot, Inc. (“The Home Depot”) pursuant to which The Home Depot may purchase up to 5.0 million shares of Common Stock at an exercise price of $2.00 per share, subject to certain vesting conditions. The THD Warrant was issued in connection with the Company’s Strategic Purchasing Agreement with The Home Depot, which it entered into on July 23, 2010 and pursuant to which it supplies The Home Depot with LED retrofit lamps and fixtures. The THD Warrant provided that 1.0 million shares of Common Stock would be eligible for vesting following each year ending December 31, 2011 through December 31, 2015, subject to The Home Depot having gross product orders from the Company, in dollar terms, that are at least 20% more than the gross product orders in the immediately preceding year. For the shares underlying the THD Warrant to be eligible for vesting following the years ending December 31, 2014 and 2015, The Home Depot would be required to extend the Strategic Purchasing Agreement for additional one-year periods beyond its initial term of three years. On August 12, 2013, the Company and The Home Depot entered into Amendment No. 1 to the Strategic Purchasing Agreement which, among other things, extended the term of the Agreement for an additional three years. As of May 25, 2012, as a result of the Series H and I Preferred Offering, the exercise price of the THD Warrants adjusted, pursuant to the terms of such warrants, from $2.00 to $1.95 per share of Common Stock. The number of shares of Common Stock into which the THD Warrants were exercisable also adjusted, pursuant to the terms of the warrant, from 5,000,000 to 5,123,715 shares. As of March 9, 2014, as a result of Follow-On Series J Offering, the exercise price of the THD Warrants adjusted, pursuant to the terms of such warrants, from $1.95 to $1.50 per share of Common Stock. The number of shares of Common Stock into which the THD Warrants were exercisable also adjusted, pursuant to the terms of the warrant, from 5,123,715 to 6,657,571 shares. Each vested portion of the THD Warrant will expire on the third anniversary following the vesting of such portion.

	As of March 31, 2014, the following warrants for the purchase of Common Stock were outstanding:


	Warrant Holder		Reason for Issuance	Number of		Exercise	Expiration Date
				Common		Price
				Shares

	Investors in rights offering		Series D Warrants		750,780	$ 4.21 to $ 4.23	March 3, 2022 through April 19, 2022

	The Home Depot		Purchasing agreement		6,657,571	$ 1.50	2014 through 2018

	RW LSG Management Holdings LLC		Riverwood Warrants		12,664,760	Variable	25-May-22

	Certain other investors		Riverwood Warrants		5,427,751	Variable	25-May-22

	Cleantech Europe II (A) LP		September 2012 Warrants		3,406,041	$ 0.72	25-Sep-22

	Cleantech Europe II (B) LP		September 2012 Warrants		593,959	$ 0.72	25-Sep-22

	Portman Limited		September 2012 Warrants		4,000,000	$ 0.72	25-Sep-22

	Aquillian Investments LLC		Private Placement Series H		830,508	$ 1.18	25-Sep-17

	Pegasus		Pegasus Warrant		10,000,000	Variable	25-May-22

	Investors in Series J offering		Series J Warrants		99,308,750	$ 0.001	3-Jan-19

	Medley		Medley Debt		10,000,000	$ 0.95	19-Feb-24

	Pegasus		Pegasus Guaranty Warrants		10,000,000	$ 0.50	19-Feb-24


					163,640,120

	As of March 31, 2014, the Series D Warrants, the warrants held by Aquillian Investments LLC and a portion of the THD Warrants were fully vested and exercisable. The September 2012 Warrants will become exercisable on October 9, 2015. Per the vesting terms discussed above, no shares issuable pursuant to the THD Warrant vested for the year ended December 31, 2013 and 1,331,514 shares issuable pursuant to the THD Warrant vested during both the years ended December 31, 2012 and 2011, for total warrants vested of 2,663,028, when the product purchases for these periods satisfied the prescribed vesting conditions, and 2,663,028 shares remain subject to vesting in accordance with similar product purchasing terms. Pursuant to the terms of the Riverwood Warrants and the Pegasus Warrant, these were not exercisable as of March 31, 2014 because the aggregate fair market value of the Company’s outstanding shares of Common Stock (as determined in accordance with the terms of the Riverwood Warrants and the Pegasus Warrant) was less than $523.9 million (subject to adjustment in accordance with the terms of the Riverwood Warrants and the Pegasus Warrant). Pursuant to the terms of the Series J Warrants, the Medley Warrants and the Pegasus Guaranty Warrants, these were not exercisable as of March 31, 2014 because the Charter Amendment was not yet effective.
	The fair value of the THD Warrant is determined using the Monte Carlo valuation method and will be adjusted at each reporting date until they have been earned for each year and these adjustments will be recorded as a reduction in the related revenue (sales incentive) from The Home Depot. As of March 31, 2014 and 2013, the Company determined that a portion of the THD Warrant was expected to vest during the period based on purchases made by The Home Depot during the three months ended March 31, 2014 and 2013 and, accordingly, recorded reductions in revenue of $91,000 and $31,000 for the three months ended March 31, 2014 and 2013, respectively.

Earnings_Loss_Per_Share

Earnings (Loss) Per Share	3 Months Ended
Earnings (Loss) Per Share	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Earnings (Loss) Per Share	'
	NOTE 11:	EARNINGS (LOSS) PER SHARE
	Pursuant to that certain letter agreement, dated January 17, 2012 from the Company to LSGC Holdings (the “LSGC Letter Agreement”), the Company agreed to indemnify LSGC Holdings for, among other things, the cost of redeeming the LSGC Holdings Class C Interests (the “Repurchase Obligation”) in the event that the Company issued preferred equity securities in excess of $80.0 million. Additionally, under the terms of the LSGC Letter Agreement, in the event that the Company would be required to indemnify LSGC Holdings under the LSGC Letter Agreement, LSGC Holdings agreed to surrender 3,750,000 shares of Common Stock to the Company less any shares of Common Stock previously distributed by LSGC Holdings to Continental Casualty Company. Following the consummation of the Series H and I Preferred Offering, the amount of preferred equity issued by the Company exceeded $80.0 million, and, as a result, LSGC Holdings, a related party, was required to redeem 15,000,000 of its issued and outstanding senior preferred member interests held by Continental Casualty Company. Upon issuance of the LSGC Letter Agreement on January 17, 2012, the Company determined that two classes of Common Stock had been established for financial reporting purposes only, with Common Stock attributable to controlling stockholders representing shares beneficially owned and controlled by Pegasus Capital and its affiliates and the Common Stock attributable to noncontrolling stockholders representing the minority interest stockholders. For the three months ended March 31, 2014 and 2013, the Company computed net loss per share of noncontrolling stockholders and controlling stockholders of Common Stock using the two-class method. Net loss from operations is initially allocated based on the underlying common shares held by controlling and noncontrolling stockholders. The allocation of the net losses attributable to the Common Stock attributable to controlling stockholders is then reduced by the amount of the deemed dividend related to the Pegasus Guaranty Warrants, while the allocation of net losses attributable to the Common Stock attributable to noncontrolling stockholders is increased by the amount of the deemed dividend related to the Pegasus Guaranty Warrants (See Note 6 for further discussion).
	The following table sets forth the computation of basic and diluted net loss per share of Common Stock:


			For the Three Months Ended March 31
			2014						2013
			Controlling			Noncontrolling			Controlling			Noncontrolling
			Stockholders			Stockholders			Stockholders			Stockholders
	Basic and diluted net income per share:
	Net loss attributable to common stock		$	(32,984,078	)	$	(7,109,885	)	$	(13,677,046	)	$	(2,801,158	)
	Deemed dividends due to the issuance of Pegasus Guaranty Warrants attributable to controlling shareholders			570,574			(570,574	)		—			—
	Deemed dividends related to the Series J Preferred Stock attributable to all shareholders			(24,843,481	)		(5,355,138	)		—			—

	Undistributed net loss		$	(57,256,985	)	$	(13,035,597	)	$	(13,677,046	)	$	(2,801,158	)


	Basic and diluted weighted average number of common shares outstanding			170,973,536			36,854,212			170,632,589			34,946,783


	Basic and diluted net loss per common share		$	(0.33	)	$	(0.35	)	$	(0.08	)	$	(0.08	)

	Basic earnings per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding for the applicable period. Diluted earnings per share is computed in the same manner as basic earnings per share except the number of shares is increased to assume exercise of potentially dilutive stock options, unvested restricted stock and contingently issuable shares using the treasury stock method and convertible preferred shares using the if-converted method, unless the effect of such increases would be anti-dilutive. The Company had 109.4 million and 497,000 common stock equivalents as of March 31, 2014 and 2013, respectively, which were not included in the diluted net loss per common share as the common stock equivalents were anti-dilutive, as a result of being in a net loss position.

Related_Party_Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	NOTE 12:	RELATED PARTY TRANSACTIONS
	On May 25, 2012, the Company entered into a Support Services Agreement (“2012 Support Services Agreement”) with Pegasus Capital, pursuant to which the Company agreed to pay Pegasus Capital $125,000 for each calendar quarter beginning on July 1, 2012, in exchange for certain support services during such periods. The 2012 Support Services Agreement expires upon the earlier of: (i) June 30, 2017; (ii) a Change of Control or (iii) a QPO. During the first 30 days of any calendar quarter, the Company has the right to terminate the 2012 Support Services Agreement, effective immediately upon written notice to Pegasus Capital. Pegasus Capital is an affiliate of Pegasus IV and LSGC Holdings, which are the Company’s largest stockholders and beneficially owned approximately 87.0% of the Company’s Common Stock as of March 31, 2014.
	On February 19, 2014, the Company entered into the Pegasus Guaranty and as consideration for the Pegasus Guaranty the Company issued the Pegasus Guaranty Warrants. The Pegasus Guaranty Warrants were valued at $3.3 million as of February 19, 2014, which was partially offset by the $2.8 million fair value of the Pegasus Guaranty, with the remaining value of $571,000 accounted for as a deemed dividend to the Company’s controlling stockholders.
	On May 25, 2012, the Company entered into the Riverwood Support Services Agreement with Riverwood Holdings, pursuant to which the Company agreed to pay Riverwood Holdings $20,000 for the period from May 25, 2012 through June 30, 2012 and thereafter $50,000 for each calendar quarter beginning on July 1, 2012, in exchange for certain support services during such periods. The Riverwood Support Services Agreement expires upon the earlier of: (i) May 25, 2022, (ii) such date that Riverwood Management and/or its affiliates directly or indirectly beneficially own less than 37.5% of the shares of Series H Preferred Stock purchased pursuant to the Preferred Offering, on an as-converted basis (together with any shares of Common Stock issued upon conversion thereof); (iii) such date that the Company and Riverwood may mutually agree in writing (iv) a Change of Control or (v) a QPO. In addition, the Company has brought in several employees of Riverwood to provide consulting services. During the three months ended March 31, 2014 and 2013, the Company incurred $609,000, and $600,000, respectively, of consulting fees for services provided by Riverwood, included in selling, distribution and administrative expenses.
	In connection with the September 2012 Preferred Offering, the Company entered into a Support Services Agreement (the “Zouk Support Services Agreement”) with Zouk, pursuant to which the Company agreed to pay Zouk $100,000 each calendar quarter beginning with the quarter ended September 30, 2012, in exchange for certain support services during such periods. The Zouk Support Services Agreement expires upon the earlier of: (i) September 25, 2022; (ii) such date that Zouk and/or its affiliates directly or indirectly beneficially own less than 37.5% of the shares of Series H Preferred Stock purchased pursuant to the September 2012 Preferred Offering, on an as-converted basis; (iii) such date that the Company and Zouk may mutually agree in writing; (iv) a Change of Control and (v) a QPO.
	On September 25, 2012, and in connection with the September 2012 Preferred Offering each of Pegasus Capital, Riverwood Holdings, Portman and Zouk entered into a Fee Waiver Letter Agreement, pursuant to which the parties agreed to suspend payment of the fees payable in connection with their respective support services or other agreements between the Company and such parties until revoked by their unanimous written consent.
	During the three months ended March 31, 2014 and 2013, the Company incurred consulting fees of $0 and $15,000, respectively, for services provided by T&M Protection Resources, primarily for the facility in Monterrey, Mexico, which were included in selling, distribution and administrative expenses. T&M Protection Resources is a security company affiliated with Pegasus Capital.
	On January 3, 2014, the Company issued 2,000 and 6,000 Series J Preferred Securities to PCA Holdings and Holdings II, respectively for total proceeds of $8.0 million. On January 9, 2014, the Company issued 4,000 Series J Preferred Securities to PCA Holdings for total proceeds of $4.0 million.
	On January 3, 2014, the Company issued 2,860 Series J Preferred Securities to Riverwood Holdings for total proceeds of $2.9 million. On January 9, 2014, the Company issued 2,570 Series J Preferred Securities to Zouk for total proceeds of $2.6 million.

Concentrations_of_Credit_Risk

Concentrations of Credit Risk	3 Months Ended
	Mar. 31, 2014
Risks And Uncertainties [Abstract]	'
Concentrations of Credit Risk	'
	NOTE 13.	CONCENTRATIONS OF CREDIT RISK
	For the three months ended March 31, 2014 and 2013, the Company had one customer whose revenue represented 78% and 47% of total revenue, respectively.
	As of March 31, 2014 and 2013, the Company had one customer whose accounts receivable balance represented 87% and 50% of accounts receivable, net of allowances, respectively.

Restructuring_Expenses

Restructuring Expenses	3 Months Ended
Restructuring Expenses	Mar. 31, 2014
Restructuring And Related Activities [Abstract]	'
Restructuring Expenses	'
	NOTE 14.	RESTRUCTURING EXPENSES
	The following table summarizes our restructuring expenses and related charges for the following periods ended March 31:


			For the Three Months Ended March 31,
			2014			2013
	Broad based reduction of facilities and personnel (1)		$	90,776		$	—
	Mexico Closing (2)			—			99,004
	Organization Optimization Initiative (3)			114,277			—


	Total		$	205,053		$	99,004


	-1	These charges relate to a significant cost reduction plan initiated during the fourth quarter of 2013 that includes moving the majority of the Company’s manufacturing to its contract manufacturers in Asia, related workforce reductions in Satellite Beach, Florida and cost reductions in our foreign subsidiaries. In addition to the charges noted above, the Company expects to incur approximately $100,000 additional expense throughout this cost reduction plan, primarily related to additional headcount reductions. These additional costs are expected to be incurred in the first half of 2014.
	-2	On September 24, 2012, the Company’s Board of Directors committed to the closing of our manufacturing facility in Mexico, which was substantially complete as of December 31, 2013. During the three months ended March 31, 2013, expenses incurred related to termination of the lease on the Mexico manufacturing facility.
	-3	In September 2011, the Company began implementing a restructuring plan designed to further increase efficiencies across the organization and lower the overall cost structure. This restructuring plan included a reduction in full time headcount in the United States, which was completed in October 2011. In 2012, the Company extended the restructuring plan to further increase efficiencies across the organization and lower its overall cost structure. The plan included a significant reduction in full time headcount in Mexico resulting from the Company’s continued shift of its manufacturing and production processes to the Company’s contract manufacturer in Mexico, the replacement of 10 members of management in the United States following the completion of the Series H and I Preferred Offering in May 2012 and the closing of the Company’s offices in the United Kingdom and Australia. For the three months ended March 31, 2014, these expenses relate to the final liquidation of the Australian entity.
	As of March 31, 2014, the accrued liability associated with the restructuring and other related charges consisted of the following:


			Workforce			Other			Total
			Reduction			Exit Costs			Total
	Accrued liability as of December 31, 2013		$	699,832		$	276,956		$	976,788
	Charges			182,100			117,960			300,060
	Reversals			—			(95,007	)		(95,007	)
	Payments			(337,270	)		(140,143	)		(477,413	)

	Accrued liability as of March 31, 2014		$	544,662		$	159,766		$	704,428

	The remaining accrual as of March 31, 2014, of $704,000 is expected to be paid during the year ending December 31, 2014.
	The restructuring and other related charges are included in the line item restructuring expenses in the condensed consolidated statement of operations and comprehensive loss.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	NOTE 15.	COMMITMENTS AND CONTINGENCIES
	Legal Proceedings
	The Company is subject to the possibility of loss contingencies arising in its business and such contingencies are accounted for in accordance with ASC Topic 450, “Contingencies.” In determining loss contingencies, the Company considers the possibility of a loss as well as the ability to reasonably estimate the amount of such loss or liability. An estimated loss is recorded when it is considered probable that a liability has been incurred and when the amount of loss can be reasonably estimated. In the ordinary course of business, the Company is routinely a defendant in or party to various pending and threatened legal claims and proceedings. The Company believes that any liability resulting from these various claims will not have a material adverse effect on its results of operations or financial condition; however, it is possible that extraordinary or unexpected legal fees could adversely impact our financial results during a particular period. During its ordinary course of business, the Company enters into obligations to defend, indemnify and/or hold harmless various customers, officers, directors, employees, and other third parties. These contractual obligations could give rise to additional litigation costs and involvement in court proceedings.
	On June 22, 2012, Geveran Investments Limited (“Geveran”), a stockholder of the Company, filed a lawsuit against the Company and several other parties in the Circuit Court of the Seventeenth Judicial Circuit in and for Broward County, Florida. On October 30, 2012, the court entered an order transferring the lawsuit to the Ninth Judicial Circuit in and for Orange County, Florida. The action, styled Geveran Investments Limited v. Lighting Science Group Corp., et al., Case No. 12-17738 (07), named as defendants the Company; Pegasus and nine other entities affiliated with Pegasus; Richard Weinberg, a former Director of the Company and former interim Chief Executive Officer of the Company and a former partner of Pegasus; Gregory Kaiser, a former Chief Financial Officer of the Company; J.P. Morgan Securities, LLC (“J.P. Morgan”); and two employees of J.P. Morgan. Geveran seeks rescission of its $25.0 million investment in the Company, as well as recovery of attorneys’ fees and court costs, jointly and severally against the Company, Pegasus, Mr. Weinberg, Mr. Kaiser, J.P. Morgan and the two J.P. Morgan employees, for alleged violation of Florida securities laws. Geveran alternatively seeks unspecified money damages, as well as recovery of court costs, for alleged common law negligent misrepresentation against these same defendants. In February 2014, Geveran filed a motion to amend their first amended complaint, seeking to assert a claim for punitive damages against the defendants; that motion has been fully briefed and is scheduled to be heard before the court on June 30, 2014. The case is currently in the discovery stage.
	The Company has retained counsel, denies liability in connection with this matter and intends to vigorously defend against the claims asserted by Geveran. While the case is in its early stages and the outcome of any litigation is inherently difficult to predict, the Company currently believes that it has strong defenses against Geveran’s claims. Nonetheless, the amount of possible loss, if any, cannot be reasonably estimated at this time. The outcome, if unfavorable, could have a material adverse effect on the Company.

	The Company believes that, subject to the terms and conditions of the relevant policies (including retention and policy limits), Directors and Officers insurance coverage will be available to cover the Company’s legal fees and costs in this matter. However, given the unspecified nature of Geveran’s maximum damage claims, or if Geveran is successful on its claim for punitive damages, insurance coverage may not be available for, or such coverage may not be sufficient to fully pay, a judgment or settlement in favor of Geveran. The Company has also been paying, and expects to continue to pay, the reasonable legal expenses incurred by J.P. Morgan and its affiliates in this lawsuit in connection with the engagement of J.P. Morgan as placement agent for the Company’s private placement with Geveran. Such payments are not covered by the Company’s insurance coverage. The engagement letter executed with J.P. Morgan provides that the Company will indemnify J.P. Morgan and its affiliates from liabilities relating to J.P. Morgan’s activities as placement agent, unless such activities are finally judicially determined to have resulted from J.P. Morgan’s bad faith, gross negligence or willful misconduct. While the case is in its early stages and the outcome of any litigation is inherently difficult to predict, the Company currently believes that it has strong defenses against Geveran’s claim for rescission that a grant of the remedy of rescission is unlikely and the amount of possible loss, if any, cannot be reasonably estimated.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	NOTE 16.	SUBSEQUENT EVENTS
	On April 25, 2014, the Company entered into a three year asset based revolving credit facility (the “FCC ABL”) with FCC, LLC d/b/a First Capital (“First Capital”) providing the Company with a borrowing capacity of up to $22.5 million, which capacity is equal to the sum of (i) 85% of the Company’s eligible accounts receivable, (ii) 60% of the Company’s eligible inventory, and (iii) qualified cash less any reserves imposed by First Capital for the benefit of the Company (collectively, the “Borrowing Base”). The Company utilized proceeds from the FCC ABL to repay its outstanding obligations under the Medley Delayed Draw Loan. Under the FCC ABL, funds may be borrowed and re-borrowed on a revolving basis, from the closing date through April 25, 2017.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. The Company’s actual results could differ from these estimates.
Restricted Cash	'
	Restricted Cash
	As of March 31, 2014, as required by the Company’s five-year term loan (the “Medley Term Loan”) with Medley Capital Corporation (“Medley”), the Company was required to maintain a minimum restricted cash balance of $3.0 million to collateralize the Medley Term Loan. As of December 31, 2013, as required by the Company’s asset-based revolving credit facility (as amended, the “Wells Fargo ABL”) with Wells Fargo Bank N.A. (“Wells Fargo”), the Company was required to maintain a minimum qualified cash balance of $5.0 million as a compensating balance against the Wells Fargo ABL. Changes in the restricted cash balance are reflected as a financing activity in the consolidated statement of cash flows.
Accounts Receivable	'
	Accounts Receivable
	The Company records accounts receivable at the invoiced amount when its products are shipped to customers or upon the completion of specific milestone billing requirements. The Company’s accounts receivable balance is recorded net of allowances for amounts not expected to be collected from customers. This allowance for doubtful accounts is the Company’s best estimate of probable credit losses in the Company’s existing accounts receivable. Estimates used in determining the allowance for doubtful accounts are based on historical collection experience, age of receivables and known collectability issues. The Company writes off accounts receivable when it becomes apparent, based upon age or customer circumstances, that such amounts will not be collected. The Company reviews its allowance for doubtful accounts on a quarterly basis. Recovery of bad debt amounts previously written off is recorded as a reduction of bad debt expense in the period the payment is collected. Generally, the Company does not require collateral for its accounts receivable and does not regularly charge interest on past due amounts. As of March 31, 2014 and December 31, 2013, the Company’s accounts receivable were reflected net of an allowance for doubtful accounts of $436,000 and $475,000, respectively.
	As of March 31, 2014, there were $17.6 million of eligible accounts receivable pledged as collateral for the two year delayed draw term loan (the “Medley Delayed Draw Loan”) entered into on February 19, 2014 with Medley. As of December 31, 2013, there were $6.8 million of eligible accounts receivable pledged as collateral for the Wells Fargo ABL.
Revenue Recognition	'
	Revenue Recognition
	The Company records revenue when its products are shipped and title passes to customers. When sales of products are subject to certain customer acceptance terms, revenue from such sales is recognized once such terms have been met. The Company also provides its customers with limited rights of return for non-conforming shipments or product warranty claims.
Product Warranties	'
	Product Warranties
	The Company generally provides a five-year limited warranty covering defective materials and workmanship of its products and such warranty may require the Company to repair, replace or reimburse the purchaser for the purchase price of the product. The estimated costs related to warranties are accrued at the time products are sold based on various factors, including the Company’s stated warranty policies and practices, the historical frequency of claims and the cost to repair or replace its products under warranty. The warranty provision is included in accrued expenses on the condensed consolidated balance sheet. Changes in the warranty provision for the three months ended March 31, 2014 were as follows:


	Warranty provision as of December 31, 2013	$	3,231,991
	Additions to provision		509,201
	Less warranty costs		(746,620	)


	Warranty provision as of March 31, 2014	$	2,994,572

Fair Value Measurements	'
	Fair Value Measurements
	Cash and cash equivalents, accounts receivable, accounts payable, amounts due under lines of credit and other short term borrowings, accrued expenses and other current liabilities are carried at amounts that approximate their fair value due to the short-term maturity of these instruments.
	The Riverwood Warrants, September 2012 Warrants and the Pegasus Commitment (each as defined in Note 9 below), the Pegasus Warrants and Series J Warrants, (each as defined in Note 8 below) and Medley Warrants and Pegasus Guaranty Warrants (each as defined in Note 6 below) were initially recorded at fair value and subsequently reflected at their fair value at the end of each reporting period.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
Summary of Significant Accounting Policies (Tables)	Mar. 31, 2014
Accounting Policies [Abstract]	'
Summary of Warranty Provision	'
	Changes in the warranty provision for the three months ended March 31, 2014 were as follows:


	Warranty provision as of December 31, 2013	$	3,231,991
	Additions to provision		509,201
	Less warranty costs		(746,620	)


	Warranty provision as of March 31, 2014	$	2,994,572

Detail_of_Certain_Balance_Shee1

Detail of Certain Balance Sheet Accounts (Tables)	3 Months Ended
Detail of Certain Balance Sheet Accounts (Tables)	Mar. 31, 2014
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'
Schedule of Inventory	'
	Inventories consisted of the following as of the dates indicated:


		March 31, 2014			December 31, 2013

	Raw materials and components	$	4,284,989		$	6,868,139
	Work-in-process		524,641			1,599,089
	Finished goods		16,432,399			10,593,891


	Total inventory, net	$	21,242,029		$	19,061,119

Schedule of Property and Equipment, Net	'
	Property and equipment, net consisted of the following as of the dates indicated:


		March 31, 2014			December 31, 2013

	Leasehold improvements	$	1,495,681		$	1,486,628
	Office furniture and equipment		1,140,269			1,141,314
	Computer hardware and software		9,035,364			8,802,484
	Tooling, production and test equipment		15,078,146			16,141,358
	Vehicles		1,420			—
	Construction-in-process		152,606			325,252

	Total property and equipment		26,903,486			27,897,036
	Accumulated depreciation		(21,726,439	)		(21,398,431	)


	Total property and equipment, net	$	5,177,047		$	6,498,605

Intangible_Assets_Tables

Intangible Assets (Tables)

3 Months Ended

Mar. 31, 2014

Goodwill And Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets

Intangible assets that have finite lives are amortized over their useful lives. The Company’s intangible assets are detailed below as of March 31, 2014 and December 31, 2013:

Cost, Less

Accumulated

Net Book

Estimated

Impairment

Amortization

Value

Remaining

Charges

Useful Life

March 31, 2014:

Technology and intellectual property

2,233,829

(174,875

)

2,058,954

2.4 to 20.0 years

December 31, 2013:

Technology and intellectual property

2,011,654

(161,243

)

1,850,411

2.7 to 20.0 years

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
Fair Value Measurements (Tables)	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Company's Financial Assets and Liabilities that were Accounted for at Fair Value on a Recurring Basis	'
	The following table sets forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of March 31, 2014, according to the valuation techniques the Company used to determine their fair values:


		Fair Value Measurement as of March 31, 2014
		Quoted Price in			Significant Other			Significant
		Active Markets for			Observable Inputs			Unobservable Inputs
		Identical Assets
		Level 1			Level 2			Level 3

	Assets (Recurring):
	Pegasus Commitment	$	—		$	—		$	1,840,000


	Liabilities (Recurring):
	Riverwood Warrants	$	—		$	—		$	7,056,079
	September 2012 Warrants		—			—			1,840,000
	Pegasus Warrant		—			—			3,900,000
	Series J Warrants		—			—			38,639,971
	Medley Warrants		—			—			3,245,315
	Pegasus Guaranty Warrants		—			—			3,418,558

		$	—		$	—		$	58,099,923

Reconciliation of the Beginning and Ending Balances for Assets and Liabilities that were Accounted for at Fair Value on a Recurring Basis	'
	The following table is a reconciliation of the beginning and ending balances for assets and liabilities that were accounted for at fair value on a recurring basis using Level 3 inputs, as defined above, for the three months ended March 31, 2014:


		Balance			Realized and unrealized			Purchases, sales,			Transfers in		Balance
		December 31, 2013			gains (losses) included			issuances and			or out of		March 31, 2014
					in net loss			settlements			Level 3
	Pegasus Commitment	$	1,407,335		$	432,665		$	—		$	—	$	1,840,000
	Riverwood Warrants		(5,002,664	)		(2,053,415	)		—			—		(7,056,079	)
	September 2012 Warrants		(1,407,335	)		(432,665	)		—			—		(1,840,000	)
	Pegasus Warrant		(2,765,047	)		(1,134,953	)		—			—		(3,900,000	)
	Series J Warrants		—			(26,134,232	)		(12,505,739	)				(38,639,971	)
	Medley Warrants		—			(74,954	)		(3,170,361	)		—		(3,245,315	)
	Pegasus Guaranty Warrants		—			(81,984	)		(3,336,574	)		—		(3,418,558	)


	Total	$	(7,767,711	)	$	(29,479,538	)	$	(18,012,674	)	$	—	$	(56,259,923	)

	The following table is a reconciliation of the beginning and ending balances for assets and liabilities that were accounted for at fair value on a recurring basis using Level 3 inputs, as defined above, for the three months ended March 31, 2013:


		Balance			Realized and unrealized			Purchases, sales,			Transfers in		Balance
		December 31, 2012			gains (losses) included			issuances and			or out of		March 31, 2013
					in net loss			settlements			Level 3
	Pegasus Commitment	$	1,360,000		$	160,000		$	—		$	—	$	1,520,000
	Riverwood Warrants		(7,960,705	)		361,850			—			—		(7,598,855	)
	September 2012 Warrants		(1,360,000	)		(160,000	)		—			—		(1,520,000	)


	Total	$	(7,960,705	)	$	361,850		$	—		$	—	$	(7,598,855	)

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	3 Months Ended
Stockholders' Equity (Tables)	Mar. 31, 2014
Equity [Abstract]	'
Schedule of Warrants for Purchase of Common Stock	'
	As of March 31, 2014, the following warrants for the purchase of Common Stock were outstanding:


	Warrant Holder	Reason for Issuance	Number of		Exercise	Expiration Date
			Common		Price
			Shares

	Investors in rights offering	Series D Warrants		750,780	$ 4.21 to $ 4.23	March 3, 2022 through April 19, 2022

	The Home Depot	Purchasing agreement		6,657,571	$ 1.50	2014 through 2018

	RW LSG Management Holdings LLC	Riverwood Warrants		12,664,760	Variable	25-May-22

	Certain other investors	Riverwood Warrants		5,427,751	Variable	25-May-22

	Cleantech Europe II (A) LP	September 2012 Warrants		3,406,041	$ 0.72	25-Sep-22

	Cleantech Europe II (B) LP	September 2012 Warrants		593,959	$ 0.72	25-Sep-22

	Portman Limited	September 2012 Warrants		4,000,000	$ 0.72	25-Sep-22

	Aquillian Investments LLC	Private Placement Series H		830,508	$ 1.18	25-Sep-17

	Pegasus	Pegasus Warrant		10,000,000	Variable	25-May-22

	Investors in Series J offering	Series J Warrants		99,308,750	$ 0.001	3-Jan-19

	Medley	Medley Debt		10,000,000	$ 0.95	19-Feb-24

	Pegasus	Pegasus Guaranty Warrants		10,000,000	$ 0.50	19-Feb-24


				163,640,120

Earnings_Loss_Per_Share_Tables

Earnings (Loss) Per Share (Tables)	3 Months Ended
Earnings (Loss) Per Share (Tables)	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Computation of Basic and Diluted Net Loss Per Share of Common Stock	'
	The following table sets forth the computation of basic and diluted net loss per share of Common Stock:


		For the Three Months Ended March 31
		2014						2013
		Controlling			Noncontrolling			Controlling			Noncontrolling
		Stockholders			Stockholders			Stockholders			Stockholders
	Basic and diluted net income per share:
	Net loss attributable to common stock	$	(32,984,078	)	$	(7,109,885	)	$	(13,677,046	)	$	(2,801,158	)
	Deemed dividends due to the issuance of Pegasus Guaranty Warrants attributable to controlling shareholders		570,574			(570,574	)		—			—
	Deemed dividends related to the Series J Preferred Stock attributable to all shareholders		(24,843,481	)		(5,355,138	)		—			—

	Undistributed net loss	$	(57,256,985	)	$	(13,035,597	)	$	(13,677,046	)	$	(2,801,158	)


	Basic and diluted weighted average number of common shares outstanding		170,973,536			36,854,212			170,632,589			34,946,783


	Basic and diluted net loss per common share	$	(0.33	)	$	(0.35	)	$	(0.08	)	$	(0.08	)

Restructuring_Expenses_Tables

Restructuring Expenses (Tables)	3 Months Ended
Restructuring Expenses (Tables)	Mar. 31, 2014
Accrued Liability Associated with Restructuring Charges	'
	The following table summarizes our restructuring expenses and related charges for the following periods ended March 31:


			For the Three Months Ended March 31,
			2014			2013
	Broad based reduction of facilities and personnel (1)		$	90,776		$	—
	Mexico Closing (2)			—			99,004
	Organization Optimization Initiative (3)			114,277			—


	Total		$	205,053		$	99,004


	-1	These charges relate to a significant cost reduction plan initiated during the fourth quarter of 2013 that includes moving the majority of the Company’s manufacturing to its contract manufacturers in Asia, related workforce reductions in Satellite Beach, Florida and cost reductions in our foreign subsidiaries. In addition to the charges noted above, the Company expects to incur approximately $100,000 additional expense throughout this cost reduction plan, primarily related to additional headcount reductions. These additional costs are expected to be incurred in the first half of 2014.
	-2	On September 24, 2012, the Company’s Board of Directors committed to the closing of our manufacturing facility in Mexico, which was substantially complete as of December 31, 2013. During the three months ended March 31, 2013, expenses incurred related to termination of the lease on the Mexico manufacturing facility.
	-3	In September 2011, the Company began implementing a restructuring plan designed to further increase efficiencies across the organization and lower the overall cost structure. This restructuring plan included a reduction in full time headcount in the United States, which was completed in October 2011. In 2012, the Company extended the restructuring plan to further increase efficiencies across the organization and lower its overall cost structure. The plan included a significant reduction in full time headcount in Mexico resulting from the Company’s continued shift of its manufacturing and production processes to the Company’s contract manufacturer in Mexico, the replacement of 10 members of management in the United States following the completion of the Series H and I Preferred Offering in May 2012 and the closing of the Company’s offices in the United Kingdom and Australia. For the three months ended March 31, 2014, these expenses relate to the final liquidation of the Australian entity.
Accrued Liabilities [Member]	'
Accrued Liability Associated with Restructuring Charges	'
	As of March 31, 2014, the accrued liability associated with the restructuring and other related charges consisted of the following:


			Workforce			Other			Total
			Reduction			Exit Costs			Total
	Accrued liability as of December 31, 2013		$	699,832		$	276,956		$	976,788
	Charges			182,100			117,960			300,060
	Reversals			—			(95,007	)		(95,007	)
	Payments			(337,270	)		(140,143	)		(477,413	)

	Accrued liability as of March 31, 2014		$	544,662		$	159,766		$	704,428

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Summary Of Significant Accounting Policies [Line Items]	'	'
Minimum qualified cash balance	$3,000,000	$5,000,000
Allowance for doubtful accounts receivable	436,000	475,000
Period of warranty on products	'5 years	'
Medley Delayed Draw Loan [Member]	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'
Term loan delay period	'2 years	'
Accounts Receivable [Member]	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'
Eligible accounts receivable pledged as collateral for the two year delayed draw term loan	17,600,000	6,800,000
Medley Term Loan [Member] \| Minimum [Member]	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'
Minimum qualified cash balance	3,000,000	'
Wells Fargo ABL [Member] \| Minimum [Member]	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'
Minimum qualified cash balance	'	$5,000,000

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Summary of Warranty Provision (Detail) (USD $)	3 Months Ended
	Mar. 31, 2014
Regulatory Assets [Abstract]	'
Warranty provision, Beginning Balance	$3,231,991
Additions to provision	509,201
Less warranty costs	-746,620
Warranty provision, Ending Balance	$2,994,572

Liquidity_and_Capital_Resource1

Liquidity and Capital Resources - Additional Information (Detail) (USD $)	3 Months Ended				0 Months Ended		3 Months Ended		3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2013	Dec. 31, 2012	Feb. 19, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014
	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2013	Dec. 31, 2012	Medley Term Loan [Member]	Medley Term Loan [Member]	Medley Delayed Draw Loan [Member]	Wells Fargo ABL [Member]	Minimum [Member]
Liquidity And Capital Resources [Line Items]	'	'	'	'	'	'	'	'	'
Accumulated deficit	($774,827,863)	($734,733,900)	'	'	'	'	'	'	'
Stockholders' deficit	-480,457,687	-410,849,963	'	'	'	'	'	'	'
Common stock, par value	$0.00	$0.00	'	'	'	'	'	'	'
Preferred stock, par value	$0.00	$0.00	'	'	'	'	'	'	'
Credit facility borrowing amount	'	'	'	'	30,500,000	'	22,500,000	50,000,000	'
Credit facility maturity period	'	'	'	'	'5 years	'	'	'	'
Cash and cash equivalents	5,313,075	11,195,412	9,615,317	15,834,077	'	'	'	'	'
Restricted cash under asset-based revolving credit facility	'	'	'	'	'	$3,000,000	'	$3,000,000	'
Maximum borrowing percentage of accounts receivable invoices	'	'	'	'	'	'	85.00%	85.00%	'
Credit facility restricted cash and cash equivalents computation eligible inventory maximum percentage	'	'	'	'	'	'	60.00%	'	'
Description of Line of Credit with Medley Delayed Draw Loan	'The Medley Delayed Draw Loan provides the Company with a borrowing capacity of up to $22.5 million, which capacity is equal to the sum of (i) 85% of the Companybs eligible accounts receivable, (ii) 60% of the Companybs eligible inventory, and (iii) qualified cash less any reserves imposed by Medley for the benefit of the Company (collectively, the bBorrowing Baseb). The Company is at all times required to maintain (i) a Borrowing Base that exceeds the amount of its outstanding borrowings under the Medley Delayed Draw Loan and (ii) $3.0 million in restricted cash. The Company is required to comply with certain specified EBITDA requirements, maintain a specified lamp sourcing percentage and comply with a maximum capital expenditure limits.	'	'	'	'	'	'	'	'
Sufficient capital to fund operations in term of months	'	'	'	'	'	'	'	'	'12 months

Detail_of_Certain_Balance_Shee2

Detail of Certain Balance Sheet Accounts - Schedule of Inventory (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Inventory Disclosure [Abstract]	'	'
Raw materials and components	$4,284,989	$6,868,139
Work-in-process	524,641	1,599,089
Finished goods	16,432,399	10,593,891
Total inventory, net	$21,242,029	$19,061,119

Detail_of_Certain_Balance_Shee3

Detail of Certain Balance Sheet Accounts - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Statement Of Financial Position [Abstract]	'	'	'
Consigned inventory	$963,000	'	$693,000
Inventory allowances	23,900,000	'	24,100,000
Depreciation related to property and equipment	$1,100,000	$2,300,000	'

Detail_of_Certain_Balance_Shee4

Detail of Certain Balance Sheet Accounts - Schedule of Property and Equipment, Net (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'
Total property and equipment	$26,903,486	$27,897,036
Accumulated depreciation	-21,726,439	-21,398,431
Total property and equipment, net	5,177,047	6,498,605
Leasehold Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Total property and equipment	1,495,681	1,486,628
Office Furniture and Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Total property and equipment	1,140,269	1,141,314
Computer Hardware and Software [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Total property and equipment	9,035,364	8,802,484
Tooling, Production and Test Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Total property and equipment	15,078,146	16,141,358
Vehicles [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Total property and equipment	1,420	'
Construction-in-process [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Total property and equipment	$152,606	$325,252

Intangible_Assets_Schedule_of_

Intangible Assets - Schedule of Intangible Assets (Detail) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Indefinite-lived Intangible Assets [Line Items]	'	'
Net Book Value	2,058,954	1,850,411
Technology and Intellectual Property [Member]	'	'
Indefinite-lived Intangible Assets [Line Items]	'	'
Cost, Less Impairment Charges	2,233,829	2,011,654
Accumulated Amortization	-174,875	-161,243
Net Book Value	2,058,954	1,850,411
Minimum [Member] \| Technology and Intellectual Property [Member]	'	'
Indefinite-lived Intangible Assets [Line Items]	'	'
Estimated Remaining Useful Life	'2 years 4 months 24 days	'2 years 8 months 12 days
Maximum [Member] \| Technology and Intellectual Property [Member]	'	'
Indefinite-lived Intangible Assets [Line Items]	'	'
Estimated Remaining Useful Life	'20 years	'20 years

Intangible_Assets_Additional_I

Intangible Assets - Additional Information (Detail) (USD $)	3 Months Ended
Intangible Assets - Additional Information (Detail) (USD $)	Mar. 31, 2014	Mar. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'	'
Amortization expense of intangible assets	$14,000	$6,000

Recovered_Sheet1

Lines of Credit and Note Payable - Additional Information (Detail) (USD $)

3 Months Ended

1 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

Mar. 31, 2014

Feb. 19, 2014

Mar. 31, 2014

Sep. 21, 2011

Mar. 31, 2014

Feb. 19, 2014

Mar. 31, 2014

Feb. 19, 2014

Mar. 31, 2014

Pre Termination Date [Member]

Post Termination Date [Member]

Pegasus Guaranty and Pegasus Guaranty Warrants [Member]

Wells Fargo ABL [Member]

Ares Capital [Member]

Medley Delayed Draw Loan [Member]

Medley Term Loan [Member]

Medley Warrants [Member]

Implied Interest Rate Analysis [Member]

LIBOR [Member]

Federal Fund Rate [Member]

Interest Rate Option One [Member]

Interest Rate Option Two [Member]

Interest Rate Option Three [Member]

Interest Expense [Member]

Commitment Fees [Member]

Initial Loan [Member]

Commitment Fees [Member]

LIBOR [Member]

Line of Credit Facility [Line Items]

Borrowing base percentage of eligible accounts

85.00%

Borrowing base percentage of eligible inventory

60.00%

Amount of liquidity requirement

$2,000,000

Outstanding amount

10,000,000

30,500,000

Additional Borrowing Capacity

12,500,000

3,000,000

Eligible collateral accounts receivable

17,600,000

Eligible collateral inventory

19,800,000

Eligible collateral cash

5,300,000

Medley Delayed Draw Loan Interest rate

'Delayed Draw Loan bears interest equal to three month LIBOR plus 12% per annum, as follows (i) up to 2% (at the Company's election) of interest may be paid as "payment in kind" by adding such accrued interest to the unpaid principal balance of the Medley Term Loan and (ii) the remainder is payable in cash monthly in arrears.

Interest floating rate

10.50%

12.00%

Accrued interest rate

2.00%

Term loan interest rate

10.70%

12.20%

Credit facility borrowing amount

50,000,000

22,500,000

30,500,000

Term loan, balance amount

26,800,000

Accretion of discount on term loan

84,399

69,000

725,000

3,200,000

84,000

Accrued interest

-69,501

70,000

Number of common shares into which warrants exercisable or exercised

163,640,120

5,000,000

Warrant exercise price per share of common stock

0.5

0.95

Warrants expire date

19-Feb-24

Fair value of warrant liabilities

3,300,000

3,200,000

Change in fair value of warrants

82,000

75,000

Debt issuance costs at fair value

2,800,000

Deemed dividends

-30,198,619

570,574

Maximum borrowing percentage of accounts receivable invoices

85.00%

Line of credit facility, maximum borrowing of accounts receivable plus of eligible inventory less certain reserves

7,500,000

Percentage added to base rate

1.00%

0.50%

3.00%

3.50%

4.00%

Interest rate added to base rate depending on credit availability

0.75%

1.25%

1.75%

Standby letter of credit

$25,000,000

Fair_Value_Measurements_Compan

Fair Value Measurements - Company's Financial Assets and Liabilities that were Accounted for at Fair Value on a Recurring Basis (Detail) (Fair Value Measurements [Member], USD $)	Mar. 31, 2014
Quoted Price in Active Markets for Identical Assets Level 1 [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Liabilities (Recurring)	'
Quoted Price in Active Markets for Identical Assets Level 1 [Member] \| Pegasus Commitment [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Assets (Recurring)	'
Quoted Price in Active Markets for Identical Assets Level 1 [Member] \| Riverwood Warrants [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Liabilities (Recurring)	'
Quoted Price in Active Markets for Identical Assets Level 1 [Member] \| September 2012 Warrants [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Liabilities (Recurring)	'
Quoted Price in Active Markets for Identical Assets Level 1 [Member] \| Pegasus Warrant [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Liabilities (Recurring)	'
Quoted Price in Active Markets for Identical Assets Level 1 [Member] \| Series J Warrants [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Liabilities (Recurring)	'
Quoted Price in Active Markets for Identical Assets Level 1 [Member] \| Medley Warrants [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Liabilities (Recurring)	'
Quoted Price in Active Markets for Identical Assets Level 1 [Member] \| Pegasus Guaranty Warrants [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Liabilities (Recurring)	'
Significant Other Observable Inputs Level 2 [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Liabilities (Recurring)	'
Significant Other Observable Inputs Level 2 [Member] \| Pegasus Commitment [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Assets (Recurring)	'
Significant Other Observable Inputs Level 2 [Member] \| Riverwood Warrants [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Liabilities (Recurring)	'
Significant Other Observable Inputs Level 2 [Member] \| September 2012 Warrants [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Liabilities (Recurring)	'
Significant Other Observable Inputs Level 2 [Member] \| Pegasus Warrant [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Liabilities (Recurring)	'
Significant Other Observable Inputs Level 2 [Member] \| Series J Warrants [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Liabilities (Recurring)	'
Significant Other Observable Inputs Level 2 [Member] \| Medley Warrants [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Liabilities (Recurring)	'
Significant Other Observable Inputs Level 2 [Member] \| Pegasus Guaranty Warrants [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Liabilities (Recurring)	'
Significant Unobservable Inputs Level 3 [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Liabilities (Recurring)	58,099,923
Significant Unobservable Inputs Level 3 [Member] \| Pegasus Commitment [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Assets (Recurring)	1,840,000
Significant Unobservable Inputs Level 3 [Member] \| Riverwood Warrants [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Liabilities (Recurring)	7,056,079
Significant Unobservable Inputs Level 3 [Member] \| September 2012 Warrants [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Liabilities (Recurring)	1,840,000
Significant Unobservable Inputs Level 3 [Member] \| Pegasus Warrant [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Liabilities (Recurring)	3,900,000
Significant Unobservable Inputs Level 3 [Member] \| Series J Warrants [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Liabilities (Recurring)	38,639,971
Significant Unobservable Inputs Level 3 [Member] \| Medley Warrants [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Liabilities (Recurring)	3,245,315
Significant Unobservable Inputs Level 3 [Member] \| Pegasus Guaranty Warrants [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Liabilities (Recurring)	$3,418,558

Fair_Value_Measurements_Reconc

Fair Value Measurements - Reconciliation of the Beginning and Ending Balances for Assets and Liabilities that were Accounted for at Fair Value on a Recurring Basis (Detail) (Significant Unobservable Inputs Level 3 [Member], USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Beginning balance	($7,767,711)	($7,960,705)
Realized and unrealized gains (losses) included in net loss	-29,479,538	361,850
Purchases, sales, issuances and settlements	-19,012,674	'
Transfers in or out of Level 3	'	'
Ending balance	-56,259,923	-7,598,855
Riverwood Warrants [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Beginning balance	-5,002,664	-7,960,705
Realized and unrealized gains (losses) included in net loss	-2,053,415	361,850
Purchases, sales, issuances and settlements	'	'
Transfers in or out of Level 3	'	'
Ending balance	-7,056,079	-7,598,855
September 2012 Warrants [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Beginning balance	-1,407,335	-1,360,000
Realized and unrealized gains (losses) included in net loss	-432,665	-160,000
Purchases, sales, issuances and settlements	'	'
Transfers in or out of Level 3	'	'
Ending balance	-1,840,000	-1,520,000
Pegasus Warrant [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Beginning balance	-2,765,047	'
Realized and unrealized gains (losses) included in net loss	-1,134,953	'
Purchases, sales, issuances and settlements	'	'
Transfers in or out of Level 3	'	'
Ending balance	-3,900,000	'
Series J Warrants [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Beginning balance	'	'
Realized and unrealized gains (losses) included in net loss	-26,134,232	'
Purchases, sales, issuances and settlements	-12,505,739	'
Transfers in or out of Level 3	'	'
Ending balance	-38,639,971	'
Medley Warrants [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Beginning balance	'	'
Realized and unrealized gains (losses) included in net loss	-74,954	'
Purchases, sales, issuances and settlements	-3,170,361	'
Transfers in or out of Level 3	'	'
Ending balance	-3,245,315	'
Pegasus Guaranty Warrants [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Beginning balance	'	'
Realized and unrealized gains (losses) included in net loss	-81,984	'
Purchases, sales, issuances and settlements	-3,336,574	'
Transfers in or out of Level 3	'	'
Ending balance	-3,418,558	'
Pegasus Commitment [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Beginning balance	1,407,335	1,360,000
Realized and unrealized gains (losses) included in net loss	432,665	160,000
Purchases, sales, issuances and settlements	'	'
Transfers in or out of Level 3	'	'
Ending balance	$1,840,000	$1,520,000

Series_J_Redeemable_Convertibl1

Series J Redeemable Convertible Preferred Stock - Additional Information (Detail) (USD $)

0 Months Ended

3 Months Ended

2 Months Ended

3 Months Ended

0 Months Ended

2 Months Ended

Sep. 25, 2012

25-May-12

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Mar. 07, 2014

Mar. 31, 2014

Sep. 11, 2013

Mar. 07, 2014

Mar. 31, 2014

Jan. 03, 2014

Mar. 31, 2014

Sep. 11, 2013

Mar. 07, 2014

Nov. 18, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 07, 2014

Nov. 18, 2013

Mar. 31, 2014

Jan. 03, 2014

Mar. 07, 2014

Nov. 18, 2013

Mar. 31, 2014

Jan. 09, 2014

Jan. 03, 2014

Mar. 07, 2014

Nov. 18, 2013

Mar. 31, 2014

Jan. 03, 2014

Mar. 07, 2014

Nov. 18, 2013

Mar. 31, 2014

Mar. 07, 2014

Mar. 31, 2014

Jan. 09, 2014

Common Stock [Member]

Series J Issuance [Member]

Pegasus Warrant [Member]

Series J Warrants [Member]

PCA Holdings [Member]

Riverwood Holdings [Member]

LSGC Holdings [Member]

May 26, 2014 Prior [Member]

May 26, 2014 After [Member]

Series J Redeemable Convertible Preferred Stock [Member]

Common Stock [Member]

Series J Issuance [Member]

Series J Warrants [Member]

LSGC Holdings II, LLC [Member]

PCA Holdings [Member]

Riverwood Holdings [Member]

other accredited investors [Member]

Zouk [Member]

Series J Issuance [Member]

Temporary Equity [Line Items]

Issuance of preferred stock

20,000

6,000

13,657

6,000

2,500

2,860

2,394

1,449

2,570

Preferred stock issued, par value per share

$0.00

Shares or units issued, price per share or unit

$1,000

Gross proceeds

$49,000,000

$67,100,000

$17,500,000

$20,000,000

Shares issued to Holdings II, in consideration for advisory services

10,000,000

Conversion price per share

$0.95

Number of times liquidation amount multiplied

1.75

Preferred units issued as Series J Securities

17,475

19,657

6,000

8,500

4,000

2,000

5,254

2,860

1,494

2,570

Right to purchase common stock

2,650

Number of common shares

163,640,120

99,308,750

10,000,000

6,625,000

6,344,100

36,191,050

Issuance of preferred stock

113,609

37,475

20,000

37,475

Additional paid-in capital

301,513,520

331,199,891

30,200,000

Percentage of total equity

2.76%

Total equity value

523,900,000

Pegasus Warrant expiration date

25-May-22

Change in fair value of warrants

1,100,000

Warrants exercise price per share of common stock

0.001

Fair value of warrant liabilities

12,400,000

Change in fair value of warrants

$26,100,000

Series_H_and_Series_I_Redeemab1

Series H and Series I Redeemable Convertible Preferred Stock - Additional Information (Detail) (USD $)

0 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

Sep. 25, 2012

25-May-12

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Sep. 25, 2012

Mar. 31, 2014

Dec. 31, 2013

Sep. 25, 2012

25-May-12

Sep. 25, 2012

Mar. 31, 2014

Dec. 31, 2013

25-May-12

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

September 2012 Warrants [Member]

Pegasus Commitment [Member]

Portman [Member]

Series H Redeemable Convertible Preferred Stock [Member]

Series I Redeemable Convertible Preferred Stock [Member]

Riverwood Warrants [Member]

September 2012 Warrant [Member]

Cleantech A [Member]

Cleantech B [Member]

Class of Stock [Line Items]

Issuance of preferred stock

113,609

49,000

60,705

62,365

6,364

Shares or units issued, price per share or unit

$1,000

Gross proceeds

$49,000,000

$67,100,000

Right to purchase common stock

18,092,511

Number of common shares

4,000,000

3,406,041

593,959

Conversion price per share

$0.95

Change in redemption value

Warrant was issued to Riverwood Management

25-May-12

Exercise percent of warrants

5.00%

Equity value of company exceeds

523,900,000

Expiration date

25-May-22

Change in fair value of warrants

433,000

160,000

2,100,000

-362,000

Number of days available for redemption of shares

'10 days

Exercise price of common stock per share

$0.72

change in fair value of commitment shares

$433,000

$160,000

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)

0 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

Aug. 12, 2013

Mar. 22, 2013

Jan. 02, 2013

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Mar. 09, 2014

Mar. 08, 2014

Dec. 31, 2012

26-May-12

25-May-12

Dec. 31, 2011

Jan. 13, 2011

Mar. 31, 2014

September 2012 Warrants [Member]

Chief Executive Officer [Member]

Fair Market Value of Warrants [Member]

Minimum [Member]

Maximum [Member]

Class of Stock [Line Items]

Expenses related to restricted stock awards

$73,000

$21,000

Stock option expense

20,000

Shares issued for compensation package

192,308

1,000,000

Common stock, shares outstanding

5,000,000

Common stock, Purchase price

Strategic Purchasing Agreement date with the home depot to supply LED retrofit lamps and fixtures

23-Jul-10

Base date to exercise price of warrant

23-Jul-10

Common stock vested shares

1,000,000

Percentage of gross product order

20.00%

Vesting date of warrants

31-Dec-14

31-Dec-15

Long- term purchase commitment additional extension time period, years

'3 years

'1 year

Long- term purchase commitment, time period, years

'3 years

Warrants exercise price per share of common stock

1.5

1.95

Number of common stock shares into which warrants exercisable or exercised

163,640,120

6,657,571

5,123,715

5,000,000

Warrant exercisable date

9-Oct-15

Shares issuable pursuant to warrant vested

1,331,514

Shares issuable pursuant to warrant vested

2,663,028

Total equity value of company

523,900,000

Revenue (increase) reduction

$91,000

$31,000

Stockholders_Equity_Schedule_o

Stockholders' Equity - Schedule of Warrants for Purchase of Common Stock (Detail)

Mar. 31, 2014

Sep. 11, 2013

Mar. 31, 2014

Pegasus Warrant [Member]

Series J Warrants [Member]

RW LSG Management Holdings LLC [Member]

Certain Other Investors [Member]

Cleantech Europe II (A) LP [Member]

Cleantech Europe II (B) LP [Member]

Portman Limited [Member]

Aquillian Investments LLC [Member]

Pegasus [Member]

Investors in Rights Offering [Member]

The Home Depot [Member]

Investors In Series J Offering [Member]

Medley Capital Corporation [Member]

Riverwood Warrants [Member]

September 2012 Warrants [Member]

Private Placement Series H [Member]

Pegasus Warrant [Member]

Pegasus Guaranty Warrants [Member]

Series D Warrants [Member]

Purchasing Agreement [Member]

Series J Warrants [Member]

Minimum [Member]

Maximum [Member]

Class of Warrant or Right [Line Items]

Number of common shares

163,640,120

10,000,000

12,664,760

5,427,751

3,406,041

593,959

4,000,000

830,508

10,000,000

750,780

6,657,571

99,308,750

10,000,000

Exercise Price

0.001

0.72

1.18

0.5

4.21

4.23

1.5

0.001

0.95

Exercise Price, Description

'Variable

Expiration Date, period start

'March 3, 2022

'2014

Expiration Date, period end

'May 25, 2022

'September 25, 2022

'September 25, 2017

'May 25, 2022

'February 19, 2024

'April 19, 2022

'2018

'January 3, 2019

'February 19, 2024

Earnings_Loss_Per_Share_Additi

Earnings (Loss) Per Share - Additional Information (Detail) (USD $)	3 Months Ended
In Millions, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Jan. 17, 2012
	Mar. 31, 2014	Mar. 31, 2013	Settlement of Repurchase Obligation [Member]
Earnings Per Common Share [Line Items]	'	'	'
Preferred equity issued	'	'	$80
Surrendering common stock	'	'	3,750,000
Redeemable preferred stock	'	'	15,000,000
Method used to compute net loss per share of noncontrolling shareholders and controlling shareholders common stock	'Two-class method	'Two-class method	'
Common stock equivalents outstanding	109,400,000	497,000	'

Earnings_Loss_Per_Share_Comput

Earnings (Loss) Per Share - Computation of Basic and Diluted Net Loss Per Share of Common Stock (Detail) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Basic and diluted net income per share:	'	'
Deemed dividends	($30,198,619)	'
Controlling Shareholders [Member]	'	'
Basic and diluted net income per share:	'	'
Net loss attributable to common stock	-32,984,078	-13,677,046
Undistributed net loss	-57,256,985	-13,677,046
Basic and diluted weighted average number of common shares outstanding	170,973,536	170,632,589
Basic and diluted net loss per common share	($0.33)	($0.08)
Controlling Shareholders [Member] \| Pegasus Warrant [Member]	'	'
Basic and diluted net income per share:	'	'
Deemed dividends	570,574	'
Controlling Shareholders [Member] \| Series J Redeemable Convertible Preferred Stock [Member]	'	'
Basic and diluted net income per share:	'	'
Deemed dividends	-24,843,481	'
Noncontrolling Shareholders [Member]	'	'
Basic and diluted net income per share:	'	'
Net loss attributable to common stock	-7,109,885	-2,801,158
Undistributed net loss	-13,035,597	-2,801,158
Basic and diluted weighted average number of common shares outstanding	36,854,212	34,946,783
Basic and diluted net loss per common share	($0.35)	($0.08)
Noncontrolling Shareholders [Member] \| Pegasus Warrant [Member]	'	'
Basic and diluted net income per share:	'	'
Deemed dividends	-570,574	'
Noncontrolling Shareholders [Member] \| Series J Redeemable Convertible Preferred Stock [Member]	'	'
Basic and diluted net income per share:	'	'
Deemed dividends	($5,355,138)	'

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (USD $)

3 Months Ended

0 Months Ended

1 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

Mar. 31, 2014

Jan. 03, 2014

Mar. 07, 2014

Sep. 30, 2012

Mar. 31, 2014

Mar. 31, 2013

25-May-12

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Feb. 19, 2014

Mar. 31, 2014

Jan. 09, 2014

Mar. 31, 2014

Jan. 03, 2014

Mar. 31, 2014

Jan. 03, 2014

Mar. 31, 2014

Jan. 03, 2014

Mar. 31, 2014

Jan. 09, 2014

Series J Redeemable Convertible Preferred Stock [Member]

Zouk Support Services Agreement [Member]

2012 Support Services Agreement [Member]

Riverwood Support Services Agreement [Member]

T&M Protection Resources [Member]

Pegasus Capital [Member]

Pegasus Guaranty Warrants [Member]

PCA Holdings [Member]

LSGC Holdings II, LLC [Member]

Riverwood Holdings [Member]

Zouk [Member]

Series H Redeemable Convertible Preferred Stock [Member]

Implied Interest Rate Analysis [Member]

Series J Redeemable Convertible Preferred Stock [Member]

Maximum [Member]

Related Party Transaction [Line Items]

Due to related parties

$100,000

$125,000

$20,000

Ownership percentage of subsidiary held in parent

87.00%

Services agreement, expiration terms

'The Zouk Support Services Agreement expires upon the earlier of (i) September 25, 2022; (ii) such date that Zouk and/or its affiliates directly or indirectly beneficially own less than 37.5% of the shares of Series H Preferred Stock purchased pursuant to the September 2012 Preferred Offering, on an as-converted basis; (iii) such date that the Company and Zouk may mutually agree in writing; (iv) a Change of Control and (v) a QPO.

'The 2012 Support Services Agreement expires upon the earlier of (i) June 30, 2017; (ii) a Change of Control or (iii) a QPO. During the first 30 days of any calendar quarter, the Company has the right to terminate the 2012 Support Services Agreement, effective immediately upon written notice to Pegasus Capital.

'The Riverwood Support Services Agreement with Riverwood Holdings, pursuant to which the Company agreed to pay Riverwood Holdings $20,000 for the period from May 25, 2012 through June 30, 2012 and thereafter $50,000 for each calendar quarter beginning on July 1, 2012, in exchange for certain support services during such periods. The Riverwood Support Services Agreement expires upon the earlier of: (i) May 25, 2022, (ii) such date that Riverwood Management and/or its affiliates directly or indirectly beneficially own less than 37.5% of the shares of Series H Preferred Stock purchased pursuant to the Preferred Offering, on an as-converted basis (together with any shares of common stock issued upon conversion thereof); (iii) such date that the Company and Riverwood may mutually agree in writing (iv) a Change of Control or (v) a QPO. In addition, the Company has brought in several employees of Riverwood to provide consulting services. During the three months ended March 31, 2014 and 2013, the Company incurred $656,000, and $600,000, respectively, of consulting fees for services provided by Riverwood, included in selling, distribution and administrative expenses.

Fair value of warrants issued

3,300,000

Debt issuance costs at fair value

2,800,000

Deemed dividends

-30,198,619

570,574

Percentage of shares owned in preferred stock

37.50%

Future Payment to Riverwood Holdings

50,000

Related party service consulting fees

609,000

600,000

Related party expense

15,000

Preferred units issued as Series J Securities

17,475

4,000

8,500

2,000

19,657

6,000

5,254

2,860

2,570

Proceeds from sale of series J preferred units

$8,000,000

$4,000,000

$2,900,000

$2,600,000

Concentrations_of_Credit_Risk_

Concentrations of Credit Risk - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
	Customer	Customer
Sales [Member]	'	'
Concentration Risk [Line Items]	'	'
Number of customers	1	1
Sales [Member] \| Customer Concentration Risk [Member]	'	'
Concentration Risk [Line Items]	'	'
Concentration risk percentage	78.00%	47.00%
Accounts Receivable [Member]	'	'
Concentration Risk [Line Items]	'	'
Number of customers	1	1
Accounts Receivable [Member] \| Customer Concentration Risk [Member]	'	'
Concentration Risk [Line Items]	'	'
Concentration risk percentage	87.00%	50.00%

Restructuring_Expenses_Summary

Restructuring Expenses - Summary of Restructuring Expenses and Related Charges (Detail) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Restructuring Cost and Reserve [Line Items]	'	'
Multi-year initiatives and related charges	$205,052	$99,004
Multi Year Initiatives [Member]	'	'
Restructuring Cost and Reserve [Line Items]	'	'
Multi-year initiatives and related charges	205,053	99,004
Multi Year Initiatives [Member] \| Facility Closing [Member]	'	'
Restructuring Cost and Reserve [Line Items]	'	'
Multi-year initiatives and related charges	90,776	'
Multi Year Initiatives [Member] \| Organization Optimization Initiative [Member]	'	'
Restructuring Cost and Reserve [Line Items]	'	'
Multi-year initiatives and related charges	114,277	'
Mexico [Member] \| Multi Year Initiatives [Member] \| Facility Closing [Member]	'	'
Restructuring Cost and Reserve [Line Items]	'	'
Multi-year initiatives and related charges	'	$99,004

Restructuring_Expenses_Summary1

Restructuring Expenses - Summary of Restructuring Expenses and Related Charges (Parenthetical) (Detail) (Multi Year Initiatives [Member], USD $)	3 Months Ended	1 Months Ended
	Mar. 31, 2014	31-May-12
		United States [Member]
		Employee
Restructuring Cost and Reserve [Line Items]	'	'
Expected additional cost	$100,000	'
Number of employees replaced	'	10

Restructuring_Expense_Accrued_

Restructuring Expense - Accrued Liability Associated with the Restructuring Charges (Detail) (USD $)	3 Months Ended
	Mar. 31, 2014
Restructuring Cost and Reserve [Line Items]	'
Accrued liability, Beginning Balance	$976,788
Charges	300,060
Reversals	-95,007
Payments	-477,413
Accrued liability, Ending Balance	704,428
Organization Optimization Initiative [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Accrued liability, Beginning Balance	699,832
Charges	182,100
Reversals	'
Payments	-337,270
Accrued liability, Ending Balance	544,662
Other Exit Costs [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Accrued liability, Beginning Balance	276,956
Charges	117,960
Reversals	-95,007
Payments	-140,143
Accrued liability, Ending Balance	$159,766

Restructuring_Expense_Addition

Restructuring Expense - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2014
Restructuring Costs [Abstract]	'
Remaining accrual	$704,000

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014
Contingencies And Commitments [Line Items]	'
Number of employee defendants in lawsuit	2
Geveran Investments Ltd. [Member]	'
Contingencies And Commitments [Line Items]	'
Investment in the company, as well as recovery of costs and attorney's fees	$25

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (Subsequent Event [Member], FCC ABL [Member], USD $)	0 Months Ended
In Millions, unless otherwise specified	Apr. 25, 2014
Subsequent Event [Member] \| FCC ABL [Member]	'
Subsequent Event [Line Items]	'
Maximum borrowing capacity under credit facility	$22.50
Maximum borrowing percentage of accounts receivable invoices	85.00%
Maximum borrowing percentage of inventory	60.00%
Revolving credit facility expiration date	25-Apr-17